
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-8258669d.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-f4a99799.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Stratification of Oligometastatic Prostate Cancer Patients by Liquid Biopsy: Clinical Insights from a Pilot Study - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="ABCBABDE92653B633DABDE0027ABBCEB.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="biomedicines">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC9219949/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="Biomedicines">
<meta name="citation_title" content="Stratification of Oligometastatic Prostate Cancer Patients by Liquid Biopsy: Clinical Insights from a Pilot Study">
<meta name="citation_author" content="Antonella Colosini">
<meta name="citation_author_institution" content="Department of Radiation Oncology, University and Spedali Civili Hospital, 25123 Brescia, Italy; a.colosini@unibs.it (A.C.); nadia.pasinetti@unibs.it (N.P.); a.guerini012@unibs.it (A.E.G.); stefano.magrini@unibs.it (S.M.M.); luca.triggiani@unibs.it (L.T.)">
<meta name="citation_author_institution" content="CREA Laboratory (Centro di Ricerca Emato-Oncologica AIL), ASST Spedali Civili of Brescia, 25123 Brescia, Italy; simona.bernardi@unibs.it (S.B.); chiara.foroni@biologo.onb.it (C.F.)">
<meta name="citation_author" content="Simona Bernardi">
<meta name="citation_author_institution" content="CREA Laboratory (Centro di Ricerca Emato-Oncologica AIL), ASST Spedali Civili of Brescia, 25123 Brescia, Italy; simona.bernardi@unibs.it (S.B.); chiara.foroni@biologo.onb.it (C.F.)">
<meta name="citation_author_institution" content="Unit of Blood Diseases and Bone Marrow Transplantation, Cell Therapies and Hematology Research Program, Department of Clinical and Experimental Sciences, University of Brescia, ASST Spedali Civili di Brescia, P.le Spedali Civili, 1, 25123 Brescia, Italy; domenico.russo@unibs.it">
<meta name="citation_author" content="Chiara Foroni">
<meta name="citation_author_institution" content="CREA Laboratory (Centro di Ricerca Emato-Oncologica AIL), ASST Spedali Civili of Brescia, 25123 Brescia, Italy; simona.bernardi@unibs.it (S.B.); chiara.foroni@biologo.onb.it (C.F.)">
<meta name="citation_author" content="Nadia Pasinetti">
<meta name="citation_author_institution" content="Department of Radiation Oncology, University and Spedali Civili Hospital, 25123 Brescia, Italy; a.colosini@unibs.it (A.C.); nadia.pasinetti@unibs.it (N.P.); a.guerini012@unibs.it (A.E.G.); stefano.magrini@unibs.it (S.M.M.); luca.triggiani@unibs.it (L.T.)">
<meta name="citation_author_institution" content="CREA Laboratory (Centro di Ricerca Emato-Oncologica AIL), ASST Spedali Civili of Brescia, 25123 Brescia, Italy; simona.bernardi@unibs.it (S.B.); chiara.foroni@biologo.onb.it (C.F.)">
<meta name="citation_author_institution" content="Radiation Oncology Service, ASST Valcamonica Esine, 25040 Esine, Italy">
<meta name="citation_author" content="Andrea Emanuele Guerini">
<meta name="citation_author_institution" content="Department of Radiation Oncology, University and Spedali Civili Hospital, 25123 Brescia, Italy; a.colosini@unibs.it (A.C.); nadia.pasinetti@unibs.it (N.P.); a.guerini012@unibs.it (A.E.G.); stefano.magrini@unibs.it (S.M.M.); luca.triggiani@unibs.it (L.T.)">
<meta name="citation_author" content="Domenico Russo">
<meta name="citation_author_institution" content="Unit of Blood Diseases and Bone Marrow Transplantation, Cell Therapies and Hematology Research Program, Department of Clinical and Experimental Sciences, University of Brescia, ASST Spedali Civili di Brescia, P.le Spedali Civili, 1, 25123 Brescia, Italy; domenico.russo@unibs.it">
<meta name="citation_author" content="Roberto Bresciani">
<meta name="citation_author_institution" content="Division of Biotechnology, Department of Molecular and Translational Medicine (DMTM), University of Brescia, 25121 Brescia, Italy; roberto.bresciani@unibs.it">
<meta name="citation_author" content="Cesare Tomasi">
<meta name="citation_author_institution" content="Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, Section of Public Health and Human Sciences, University of Brescia, 25121 Brescia, Italy; cesare.tomasi@live.com">
<meta name="citation_author" content="Stefano Maria Magrini">
<meta name="citation_author_institution" content="Department of Radiation Oncology, University and Spedali Civili Hospital, 25123 Brescia, Italy; a.colosini@unibs.it (A.C.); nadia.pasinetti@unibs.it (N.P.); a.guerini012@unibs.it (A.E.G.); stefano.magrini@unibs.it (S.M.M.); luca.triggiani@unibs.it (L.T.)">
<meta name="citation_author" content="Lilia Bardoscia">
<meta name="citation_author_institution" content="Department of Radiation Oncology, University and Spedali Civili Hospital, 25123 Brescia, Italy; a.colosini@unibs.it (A.C.); nadia.pasinetti@unibs.it (N.P.); a.guerini012@unibs.it (A.E.G.); stefano.magrini@unibs.it (S.M.M.); luca.triggiani@unibs.it (L.T.)">
<meta name="citation_author_institution" content="Radiation Oncology Unit, S. Luca Hospital, Healthcare Company Tuscany Nord Ovest, 55100 Lucca, Italy">
<meta name="citation_author" content="Luca Triggiani">
<meta name="citation_author_institution" content="Department of Radiation Oncology, University and Spedali Civili Hospital, 25123 Brescia, Italy; a.colosini@unibs.it (A.C.); nadia.pasinetti@unibs.it (N.P.); a.guerini012@unibs.it (A.E.G.); stefano.magrini@unibs.it (S.M.M.); luca.triggiani@unibs.it (L.T.)">
<meta name="citation_author_institution" content="CREA Laboratory (Centro di Ricerca Emato-Oncologica AIL), ASST Spedali Civili of Brescia, 25123 Brescia, Italy; simona.bernardi@unibs.it (S.B.); chiara.foroni@biologo.onb.it (C.F.)">
<meta name="citation_publication_date" content="2022 Jun 4">
<meta name="citation_volume" content="10">
<meta name="citation_issue" content="6">
<meta name="citation_firstpage" content="1321">
<meta name="citation_doi" content="10.3390/biomedicines10061321">
<meta name="citation_pmid" content="35740343">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC9219949/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC9219949/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC9219949/pdf/biomedicines-10-01321.pdf">
<meta name="description" content="We propose a pilot, prospective, translational study with the aim of identifying possible molecular markers underlying metastatic prostate cancer (PC) evolution with the use of liquid biopsy. Twenty-eight castrate sensitive, oligometastatic PC ...">
<meta name="og:title" content="Stratification of Oligometastatic Prostate Cancer Patients by Liquid Biopsy: Clinical Insights from a Pilot Study">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="We propose a pilot, prospective, translational study with the aim of identifying possible molecular markers underlying metastatic prostate cancer (PC) evolution with the use of liquid biopsy. Twenty-eight castrate sensitive, oligometastatic PC ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC9219949/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-header data-testid="header"    >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            <a class="ncbi-header__logo-container"
               href="https://www.ncbi.nlm.nih.gov/">
                <img alt="NCBI home page"
                     class="ncbi-header__logo-image"
                     src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg"
                     width="410"
                     height="100" />
            </a>

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="desktop-navigation-search-form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only" for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  action="https://www.ncbi.nlm.nih.gov/search/all/"
                  
                  autocomplete="off"
                  data-testid="mobile-navigation-search-form"
                  method="GET"
                  role="search">
                <label class="usa-sr-only" for="search-field-mobile-navigation">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="term" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://pmc.ncbi.nlm.nih.gov/search/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="9219949">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.3390/biomedicines10061321"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/biomedicines-10-01321.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC9219949%2F%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/9219949/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/9219949/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC9219949/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-biomedicines.png" alt="Biomedicines logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to Biomedicines" title="Link to Biomedicines" shape="default" href="http://www.mdpi.com/journal/biomedicines" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">Biomedicines</button></div>. 2022 Jun 4;10(6):1321. doi: <a href="https://doi.org/10.3390/biomedicines10061321" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.3390/biomedicines10061321</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://pmc.ncbi.nlm.nih.gov/search/?term=%22Biomedicines%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Biomedicines%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Biomedicines%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22Biomedicines%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Stratification of Oligometastatic Prostate Cancer Patients by Liquid Biopsy: Clinical Insights from a Pilot Study</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Colosini%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Antonella Colosini</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Antonella Colosini</span></h3>
<div class="p">
<sup>1</sup>Department of Radiation Oncology, University and Spedali Civili Hospital, 25123 Brescia, Italy; a.colosini@unibs.it (A.C.); nadia.pasinetti@unibs.it (N.P.); a.guerini012@unibs.it (A.E.G.); stefano.magrini@unibs.it (S.M.M.); luca.triggiani@unibs.it (L.T.)</div>
<div class="p">
<sup>2</sup>CREA Laboratory (Centro di Ricerca Emato-Oncologica AIL), ASST Spedali Civili of Brescia, 25123 Brescia, Italy; simona.bernardi@unibs.it (S.B.); chiara.foroni@biologo.onb.it (C.F.)</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Colosini%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">Antonella Colosini</span></a>
</div>
</div>
<sup>1,</sup><sup>2,</sup><sup>†</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Bernardi%20S%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Simona Bernardi</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Simona Bernardi</span></h3>
<div class="p">
<sup>2</sup>CREA Laboratory (Centro di Ricerca Emato-Oncologica AIL), ASST Spedali Civili of Brescia, 25123 Brescia, Italy; simona.bernardi@unibs.it (S.B.); chiara.foroni@biologo.onb.it (C.F.)</div>
<div class="p">
<sup>3</sup>Unit of Blood Diseases and Bone Marrow Transplantation, Cell Therapies and Hematology Research Program, Department of Clinical and Experimental Sciences, University of Brescia, ASST Spedali Civili di Brescia, P.le Spedali Civili, 1, 25123 Brescia, Italy; domenico.russo@unibs.it</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Bernardi%20S%22%5BAuthor%5D" class="usa-link"><span class="name western">Simona Bernardi</span></a>
</div>
</div>
<sup>2,</sup><sup>3,</sup><sup>†</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Foroni%20C%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Chiara Foroni</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Chiara Foroni</span></h3>
<div class="p">
<sup>2</sup>CREA Laboratory (Centro di Ricerca Emato-Oncologica AIL), ASST Spedali Civili of Brescia, 25123 Brescia, Italy; simona.bernardi@unibs.it (S.B.); chiara.foroni@biologo.onb.it (C.F.)</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Foroni%20C%22%5BAuthor%5D" class="usa-link"><span class="name western">Chiara Foroni</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Pasinetti%20N%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Nadia Pasinetti</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Nadia Pasinetti</span></h3>
<div class="p">
<sup>1</sup>Department of Radiation Oncology, University and Spedali Civili Hospital, 25123 Brescia, Italy; a.colosini@unibs.it (A.C.); nadia.pasinetti@unibs.it (N.P.); a.guerini012@unibs.it (A.E.G.); stefano.magrini@unibs.it (S.M.M.); luca.triggiani@unibs.it (L.T.)</div>
<div class="p">
<sup>2</sup>CREA Laboratory (Centro di Ricerca Emato-Oncologica AIL), ASST Spedali Civili of Brescia, 25123 Brescia, Italy; simona.bernardi@unibs.it (S.B.); chiara.foroni@biologo.onb.it (C.F.)</div>
<div class="p">
<sup>4</sup>Radiation Oncology Service, ASST Valcamonica Esine, 25040 Esine, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Pasinetti%20N%22%5BAuthor%5D" class="usa-link"><span class="name western">Nadia Pasinetti</span></a>
</div>
</div>
<sup>1,</sup><sup>2,</sup><sup>4</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Guerini%20AE%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Andrea Emanuele Guerini</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">Andrea Emanuele Guerini</span></h3>
<div class="p">
<sup>1</sup>Department of Radiation Oncology, University and Spedali Civili Hospital, 25123 Brescia, Italy; a.colosini@unibs.it (A.C.); nadia.pasinetti@unibs.it (N.P.); a.guerini012@unibs.it (A.E.G.); stefano.magrini@unibs.it (S.M.M.); luca.triggiani@unibs.it (L.T.)</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Guerini%20AE%22%5BAuthor%5D" class="usa-link"><span class="name western">Andrea Emanuele Guerini</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Russo%20D%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">Domenico Russo</span></a><div hidden="hidden" id="id6">
<h3><span class="name western">Domenico Russo</span></h3>
<div class="p">
<sup>3</sup>Unit of Blood Diseases and Bone Marrow Transplantation, Cell Therapies and Hematology Research Program, Department of Clinical and Experimental Sciences, University of Brescia, ASST Spedali Civili di Brescia, P.le Spedali Civili, 1, 25123 Brescia, Italy; domenico.russo@unibs.it</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Russo%20D%22%5BAuthor%5D" class="usa-link"><span class="name western">Domenico Russo</span></a>
</div>
</div>
<sup>3</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Bresciani%20R%22%5BAuthor%5D" class="usa-link" aria-describedby="id7"><span class="name western">Roberto Bresciani</span></a><div hidden="hidden" id="id7">
<h3><span class="name western">Roberto Bresciani</span></h3>
<div class="p">
<sup>5</sup>Division of Biotechnology, Department of Molecular and Translational Medicine (DMTM), University of Brescia, 25121 Brescia, Italy; roberto.bresciani@unibs.it</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Bresciani%20R%22%5BAuthor%5D" class="usa-link"><span class="name western">Roberto Bresciani</span></a>
</div>
</div>
<sup>5</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Tomasi%20C%22%5BAuthor%5D" class="usa-link" aria-describedby="id8"><span class="name western">Cesare Tomasi</span></a><div hidden="hidden" id="id8">
<h3><span class="name western">Cesare Tomasi</span></h3>
<div class="p">
<sup>6</sup>Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, Section of Public Health and Human Sciences, University of Brescia, 25121 Brescia, Italy; cesare.tomasi@live.com</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Tomasi%20C%22%5BAuthor%5D" class="usa-link"><span class="name western">Cesare Tomasi</span></a>
</div>
</div>
<sup>6</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Magrini%20SM%22%5BAuthor%5D" class="usa-link" aria-describedby="id9"><span class="name western">Stefano Maria Magrini</span></a><div hidden="hidden" id="id9">
<h3><span class="name western">Stefano Maria Magrini</span></h3>
<div class="p">
<sup>1</sup>Department of Radiation Oncology, University and Spedali Civili Hospital, 25123 Brescia, Italy; a.colosini@unibs.it (A.C.); nadia.pasinetti@unibs.it (N.P.); a.guerini012@unibs.it (A.E.G.); stefano.magrini@unibs.it (S.M.M.); luca.triggiani@unibs.it (L.T.)</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Magrini%20SM%22%5BAuthor%5D" class="usa-link"><span class="name western">Stefano Maria Magrini</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Bardoscia%20L%22%5BAuthor%5D" class="usa-link" aria-describedby="id10"><span class="name western">Lilia Bardoscia</span></a><div hidden="hidden" id="id10">
<h3><span class="name western">Lilia Bardoscia</span></h3>
<div class="p">
<sup>1</sup>Department of Radiation Oncology, University and Spedali Civili Hospital, 25123 Brescia, Italy; a.colosini@unibs.it (A.C.); nadia.pasinetti@unibs.it (N.P.); a.guerini012@unibs.it (A.E.G.); stefano.magrini@unibs.it (S.M.M.); luca.triggiani@unibs.it (L.T.)</div>
<div class="p">
<sup>7</sup>Radiation Oncology Unit, S. Luca Hospital, Healthcare Company Tuscany Nord Ovest, 55100 Lucca, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Bardoscia%20L%22%5BAuthor%5D" class="usa-link"><span class="name western">Lilia Bardoscia</span></a>
</div>
</div>
<sup>1,</sup><sup>7,</sup><sup>*,</sup><sup>‡</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Triggiani%20L%22%5BAuthor%5D" class="usa-link" aria-describedby="id11"><span class="name western">Luca Triggiani</span></a><div hidden="hidden" id="id11">
<h3><span class="name western">Luca Triggiani</span></h3>
<div class="p">
<sup>1</sup>Department of Radiation Oncology, University and Spedali Civili Hospital, 25123 Brescia, Italy; a.colosini@unibs.it (A.C.); nadia.pasinetti@unibs.it (N.P.); a.guerini012@unibs.it (A.E.G.); stefano.magrini@unibs.it (S.M.M.); luca.triggiani@unibs.it (L.T.)</div>
<div class="p">
<sup>2</sup>CREA Laboratory (Centro di Ricerca Emato-Oncologica AIL), ASST Spedali Civili of Brescia, 25123 Brescia, Italy; simona.bernardi@unibs.it (S.B.); chiara.foroni@biologo.onb.it (C.F.)</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Triggiani%20L%22%5BAuthor%5D" class="usa-link"><span class="name western">Luca Triggiani</span></a>
</div>
</div>
<sup>1,</sup><sup>2,</sup><sup>‡</sup>
</div>
<div class="cg p">Editors: <span class="name western">Claudio Luparello</span>, <span class="name western">Rita Ferreira</span>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="af1-biomedicines-10-01321">
<sup>1</sup>Department of Radiation Oncology, University and Spedali Civili Hospital, 25123 Brescia, Italy; a.colosini@unibs.it (A.C.); nadia.pasinetti@unibs.it (N.P.); a.guerini012@unibs.it (A.E.G.); stefano.magrini@unibs.it (S.M.M.); luca.triggiani@unibs.it (L.T.)</div>
<div id="af2-biomedicines-10-01321">
<sup>2</sup>CREA Laboratory (Centro di Ricerca Emato-Oncologica AIL), ASST Spedali Civili of Brescia, 25123 Brescia, Italy; simona.bernardi@unibs.it (S.B.); chiara.foroni@biologo.onb.it (C.F.)</div>
<div id="af3-biomedicines-10-01321">
<sup>3</sup>Unit of Blood Diseases and Bone Marrow Transplantation, Cell Therapies and Hematology Research Program, Department of Clinical and Experimental Sciences, University of Brescia, ASST Spedali Civili di Brescia, P.le Spedali Civili, 1, 25123 Brescia, Italy; domenico.russo@unibs.it</div>
<div id="af4-biomedicines-10-01321">
<sup>4</sup>Radiation Oncology Service, ASST Valcamonica Esine, 25040 Esine, Italy</div>
<div id="af5-biomedicines-10-01321">
<sup>5</sup>Division of Biotechnology, Department of Molecular and Translational Medicine (DMTM), University of Brescia, 25121 Brescia, Italy; roberto.bresciani@unibs.it</div>
<div id="af6-biomedicines-10-01321">
<sup>6</sup>Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, Section of Public Health and Human Sciences, University of Brescia, 25121 Brescia, Italy; cesare.tomasi@live.com</div>
<div id="af7-biomedicines-10-01321">
<sup>7</sup>Radiation Oncology Unit, S. Luca Hospital, Healthcare Company Tuscany Nord Ovest, 55100 Lucca, Italy</div>
<div class="author-notes p">
<div class="fn" id="c1-biomedicines-10-01321">
<sup>*</sup><p class="display-inline">Correspondence: <span>lilia.bardoscia@uslnordovest.toscana.it</span> or <span>liliabardoscia@gmail.com</span></p>
</div>
<div class="fn" id="fn1-biomedicines-10-01321">
<sup>†</sup><p class="display-inline">These authors contributed equally to this work.</p>
</div>
<div class="fn" id="fn2-biomedicines-10-01321">
<sup>‡</sup><p class="display-inline">These authors contributed equally to this work.</p>
</div>
</div>
<h4 class="font-secondary">Roles</h4>
<div class="p">
<strong class="contrib"><span class="name western">Claudio Luparello</span></strong>: <span class="role">Academic Editor</span>
</div>
<div>
<strong class="contrib"><span class="name western">Rita Ferreira</span></strong>: <span class="role">Academic Editor</span>
</div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Received 2022 May 11; Accepted 2022 Jun 2; Collection date 2022 Jun.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>© 2022 by the authors.</div>
<p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<a href="https://creativecommons.org/licenses/by/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://creativecommons.org/licenses/by/4.0/</a>).</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC9219949  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/35740343/" class="usa-link">35740343</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="abstract1"><h2>Abstract</h2>
<p>We propose a pilot, prospective, translational study with the aim of identifying possible molecular markers underlying metastatic prostate cancer (PC) evolution with the use of liquid biopsy. Twenty-eight castrate sensitive, oligometastatic PC patients undergoing bone and/or nodal stereotactic body radiotherapy (SBRT) were recruited. Peripheral blood samples were collected before the commencement of SBRT, then they were processed for circulating cell free DNA (cfDNA) extraction. Deep targeted sequencing was performed using a custom gene panel. The primary endpoint was to identify differences in the molecular contribution between the oligometastatic and polymetastatic evolution of PC to same-first oligo-recurrent disease presentation. Seventy-seven mutations were detected in 25/28 cfDNA samples: ATM in 14 (50%) cases, BRCA2 11 (39%), BRCA1 6 (21%), AR 13 (46%), ETV4, and ETV6 2 (7%). SBRT failure was associated with an increased risk of harboring the BRCA1 mutation (OR 10.5) (<em>p</em> = 0.043). The median cfDNA concentration was 24.02 ng/mL for ATM mutation carriers vs. 40.04 ng/mL for non-carriers (<em>p</em> = 0.039). Real-time molecular characterization of oligometastatic PC may allow for the identification of a true oligometastatic phenotype, with a stable disease over a long time being more likely to benefit from local, curative treatments or the achievement of long-term disease control. A prospective validation of our promising findings is desirable for a better understanding of the real impact of liquid biopsy in detecting tumor aggressiveness and clonal evolution.</p>
<section id="kwd-group1" class="kwd-group"><p><strong>Keywords:</strong> oligometastatic state, prostate cancer, stereotactic body radiotherapy, liquid biopsy, circulating cell free DNA, deep targeted sequencing</p></section></section><section id="sec1-biomedicines-10-01321"><h2 class="pmc_sec_title">1. Introduction</h2>
<p>Oligometastatic prostate cancer (OPC) is a heterogeneous disease encompassing a broad spectrum of clinical states and related outcomes, such as de novo oligometastatic, oligorecurrent, and oligoprogressive disease [<a href="#B1-biomedicines-10-01321" class="usa-link" aria-describedby="B1-biomedicines-10-01321">1</a>,<a href="#B2-biomedicines-10-01321" class="usa-link" aria-describedby="B2-biomedicines-10-01321">2</a>,<a href="#B3-biomedicines-10-01321" class="usa-link" aria-describedby="B3-biomedicines-10-01321">3</a>,<a href="#B4-biomedicines-10-01321" class="usa-link" aria-describedby="B4-biomedicines-10-01321">4</a>]. The oligometastases theory was proposed for the first time in 1995 by Hellman and Weichselbaum, suggesting that metastatic dissemination occurs along an only apparent continuum from localized cancer to extensively metastatic disease [<a href="#B2-biomedicines-10-01321" class="usa-link" aria-describedby="B2-biomedicines-10-01321">2</a>,<a href="#B3-biomedicines-10-01321" class="usa-link" aria-describedby="B3-biomedicines-10-01321">3</a>]. Oligometastatic disease has been described to show a relatively limited metastatic potential [<a href="#B4-biomedicines-10-01321" class="usa-link" aria-describedby="B4-biomedicines-10-01321">4</a>]. In the natural history of prostate cancer, OPC may represent the initial step of an unavoidable, rapid progression to a polymetastatic state, or it may be the expression of a true oligometastatic phenotype; hence, a stable disease for a long time, and amenable to curative treatment or the achievement of long-term disease control [<a href="#B5-biomedicines-10-01321" class="usa-link" aria-describedby="B5-biomedicines-10-01321">5</a>,<a href="#B6-biomedicines-10-01321" class="usa-link" aria-describedby="B6-biomedicines-10-01321">6</a>,<a href="#B7-biomedicines-10-01321" class="usa-link" aria-describedby="B7-biomedicines-10-01321">7</a>]. To date, OPC is mainly defined according to a maximum number of distant metastatic lesions (usually 1 to 3) [<a href="#B8-biomedicines-10-01321" class="usa-link" aria-describedby="B8-biomedicines-10-01321">8</a>]. In the oligometastatic setting, the adoption of stereotactic body radiation therapy (SBRT) has proven to be a potentially curative treatment option. A large amount of retrospective, national, and international studies have already described SBRT as being safe and effective in terms of local control of disease and freedom from failure [<a href="#B9-biomedicines-10-01321" class="usa-link" aria-describedby="B9-biomedicines-10-01321">9</a>,<a href="#B10-biomedicines-10-01321" class="usa-link" aria-describedby="B10-biomedicines-10-01321">10</a>,<a href="#B11-biomedicines-10-01321" class="usa-link" aria-describedby="B11-biomedicines-10-01321">11</a>,<a href="#B12-biomedicines-10-01321" class="usa-link" aria-describedby="B12-biomedicines-10-01321">12</a>,<a href="#B13-biomedicines-10-01321" class="usa-link" aria-describedby="B13-biomedicines-10-01321">13</a>,<a href="#B14-biomedicines-10-01321" class="usa-link" aria-describedby="B14-biomedicines-10-01321">14</a>,<a href="#B15-biomedicines-10-01321" class="usa-link" aria-describedby="B15-biomedicines-10-01321">15</a>,<a href="#B16-biomedicines-10-01321" class="usa-link" aria-describedby="B16-biomedicines-10-01321">16</a>,<a href="#B17-biomedicines-10-01321" class="usa-link" aria-describedby="B17-biomedicines-10-01321">17</a>,<a href="#B18-biomedicines-10-01321" class="usa-link" aria-describedby="B18-biomedicines-10-01321">18</a>,<a href="#B19-biomedicines-10-01321" class="usa-link" aria-describedby="B19-biomedicines-10-01321">19</a>,<a href="#B20-biomedicines-10-01321" class="usa-link" aria-describedby="B20-biomedicines-10-01321">20</a>,<a href="#B21-biomedicines-10-01321" class="usa-link" aria-describedby="B21-biomedicines-10-01321">21</a>,<a href="#B22-biomedicines-10-01321" class="usa-link" aria-describedby="B22-biomedicines-10-01321">22</a>,<a href="#B23-biomedicines-10-01321" class="usa-link" aria-describedby="B23-biomedicines-10-01321">23</a>,<a href="#B24-biomedicines-10-01321" class="usa-link" aria-describedby="B24-biomedicines-10-01321">24</a>,<a href="#B25-biomedicines-10-01321" class="usa-link" aria-describedby="B25-biomedicines-10-01321">25</a>,<a href="#B26-biomedicines-10-01321" class="usa-link" aria-describedby="B26-biomedicines-10-01321">26</a>,<a href="#B27-biomedicines-10-01321" class="usa-link" aria-describedby="B27-biomedicines-10-01321">27</a>,<a href="#B28-biomedicines-10-01321" class="usa-link" aria-describedby="B28-biomedicines-10-01321">28</a>,<a href="#B29-biomedicines-10-01321" class="usa-link" aria-describedby="B29-biomedicines-10-01321">29</a>,<a href="#B30-biomedicines-10-01321" class="usa-link" aria-describedby="B30-biomedicines-10-01321">30</a>], owing to the postponement of the need for androgen deprivation therapy (ADT) prescription, which still represents the standard of care for metastatic prostate cancer. Such findings were recently confirmed by prospective series, and they definitely supported the role of metastases-directed therapy in OPC patients relapsing after a local treatment with a limited number of metastases [<a href="#B31-biomedicines-10-01321" class="usa-link" aria-describedby="B31-biomedicines-10-01321">31</a>,<a href="#B32-biomedicines-10-01321" class="usa-link" aria-describedby="B32-biomedicines-10-01321">32</a>,<a href="#B33-biomedicines-10-01321" class="usa-link" aria-describedby="B33-biomedicines-10-01321">33</a>,<a href="#B34-biomedicines-10-01321" class="usa-link" aria-describedby="B34-biomedicines-10-01321">34</a>].</p>
<p>Despite significant advances in understanding the clinical meaning of OPC, no biomarkers that differentiate between the oligometastatic and the polymetastatic state have been currently validated, and biological investigations for OPC patient stratification are still lacking in literature. Over the past years, molecular profiling has improved our knowledge regarding the genomic landscape of advanced prostate cancer [<a href="#B35-biomedicines-10-01321" class="usa-link" aria-describedby="B35-biomedicines-10-01321">35</a>,<a href="#B36-biomedicines-10-01321" class="usa-link" aria-describedby="B36-biomedicines-10-01321">36</a>]. For this purpose, the so-called “liquid biopsy” approach may provide a powerful tool for identifying predictive biomarkers and therapeutic targets in a non-invasive manner [<a href="#B37-biomedicines-10-01321" class="usa-link" aria-describedby="B37-biomedicines-10-01321">37</a>]. Moreover, molecular biology techniques such as next-generation sequencing (NGS) have emerged as a promising issue for characterizing the oligometastatic-state heterogeneity [<a href="#B38-biomedicines-10-01321" class="usa-link" aria-describedby="B38-biomedicines-10-01321">38</a>,<a href="#B39-biomedicines-10-01321" class="usa-link" aria-describedby="B39-biomedicines-10-01321">39</a>]. We present our pilot study, the translational analysis of serum-derived circulating cell free DNA (cfDNA) in a population of OPC patients, using a deep target sequencing approach, with the aim of tracking metastatic prostate cancer spread from a molecular point of view, the possible identification of biomarkers that are predictive for a true oligometastatic state, and we assess whether any molecular characterization of OPC may also contribute to select patients that are more likely to benefit from local, metastasis-directed SBRT [<a href="#B40-biomedicines-10-01321" class="usa-link" aria-describedby="B40-biomedicines-10-01321">40</a>].</p></section><section id="sec2-biomedicines-10-01321"><h2 class="pmc_sec_title">2. Materials and Methods</h2>
<section id="sec2dot1-biomedicines-10-01321"><h3 class="pmc_sec_title">2.1. Patients Selection and Treatment</h3>
<p>The present study received final approval by the Institutional Ethical Committee, and it was performed in accordance with the principles of good clinical practice (GCP) with respect to the ICH GCP guidelines and the ethical principles contained in the Helsinki declaration [<a href="#B41-biomedicines-10-01321" class="usa-link" aria-describedby="B41-biomedicines-10-01321">41</a>].</p>
<p>The study population included adult patients with castrate-sensitive OPC, consecutively evaluated at our institution for SBRT on bone lesions (30 Gy/3 fractions, biological effective dose (BED) 108 Gy, considering α/ß 3 Gy) or nodal metastases (36 Gy/6 fractions, BED 100 Gy considering α/ß 1.5 Gy for cancer and 3 Gy for late-responder normal tissue). Inclusion criteria are reported in <a href="#biomedicines-10-01321-t001" class="usa-link">Table 1</a>.</p>
<section class="tw xbox font-sm" id="biomedicines-10-01321-t001"><h4 class="obj_head">Table 1.</h4>
<div class="caption p"><p>Patient selection criteria.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups"><tbody>
<tr><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<strong>Inclusion Criteria</strong>
</td></tr>
<tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<ol class="list" style="list-style-type:decimal">
<li><p>18 years old</p></li>
<li><p>Pathologically confirmed acinar adenocarcinoma of prostate</p></li>
<li><p>Castrate-sensitive OPC: ≤ 3 lesions (bone or node) detected with choline/PSMA PET following prostate specific antigen (PSA) rising after primary treatment with curative intent as defined by European Association of Urology criteria (EAU)</p></li>
<li><p>Patients eligible for a course of SBRT</p></li>
<li><p>Patients amenable to sign written informed consent</p></li>
</ol>
</td></tr>
<tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>Exclusion criteria</strong>
</td></tr>
<tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<ol class="list" style="list-style-type:decimal">
<li><p>Ongoing ADT (stopped &lt;6 months before baseline evaluation)</p></li>
<li><p>Prior treatment for castrate-sensitive OPC</p></li>
<li><p>Testosterone levels &lt;50 ng/mL</p></li>
</ol>
</td></tr>
</tbody></table></div>
<div class="p text-right font-secondary"><a href="table/biomedicines-10-01321-t001/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></section><p>All of the metastatic lesions (bone and lymph nodes) had been detected by restaging 11C-Choline PET/CT scan, and/or 68Ga-Prostate-Specific Membrane Antigen (PSMA) PET/CT scan, at the time of biochemical failure after primary treatment with curative intent according to the European Association of Urology (EAU) guidelines [<a href="#B42-biomedicines-10-01321" class="usa-link" aria-describedby="B42-biomedicines-10-01321">42</a>].</p>
<p>Radiotherapy planning and treatment delivery are fully described in <a href="#app1-biomedicines-10-01321" class="usa-link">Appendix A</a>—Radiotherapy Procedures.</p>
<p>Following SBRT, all the enrolled patients underwent clinical follow up as per usual, according to disease-specific, internationally accepted clinical practice [<a href="#B42-biomedicines-10-01321" class="usa-link" aria-describedby="B42-biomedicines-10-01321">42</a>] (details in <a href="#app1-biomedicines-10-01321" class="usa-link">Appendix A</a>—Radiotherapy Procedures). For the purpose of the present protocol, data collection continued for a planned observation period of 36 months after the treatment of OPC.</p></section><section id="sec2dot2-biomedicines-10-01321"><h3 class="pmc_sec_title">2.2. Biological Experimental Plan</h3>
<section id="sec2dot2dot1-biomedicines-10-01321"><h4 class="pmc_sec_title">2.2.1. cfDNA Extraction and Sequencing</h4>
<p>Per each enrolled patient, peripheral blood samples were collected in 2 × 4.9 mL clot activator tubes (S-Monovette Sarstedt) before the start of SBRT, and kept at room temperature for 30–60 min to allow for clotting, and then centrifuged at 2000× <em>g</em> for 15 at 4 °C. Circulating cell free DNA (cfDNA) was purified from serum using QIAamp Circulating Nucleic Acid kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. cfDNA was quantified using QuantiT™ Oligreen<sup>®</sup> ssDNA kit (Thermofisher, Waltham, MA, USA) and Infinite200 plate reader (Tecan, Männedorf, Switzerland).</p></section><section id="sec2dot2dot2-biomedicines-10-01321"><h4 class="pmc_sec_title">2.2.2. Library Preparation and NGS Analysis</h4>
<p>After extraction, cfDNA from serum immediately underwent end-repair, A-tailing, and ligation to Illumina indexed adapters.</p>
<p>A custom-targeted gene panel was designed following the evidences reported in the literature regarding the molecular characterization of prostate cancer [<a href="#B35-biomedicines-10-01321" class="usa-link" aria-describedby="B35-biomedicines-10-01321">35</a>,<a href="#B43-biomedicines-10-01321" class="usa-link" aria-describedby="B43-biomedicines-10-01321">43</a>], using the NimbleDesign tool (Roche, Basel, Switzerland), and included the coding sequence (exons) of the genes showed in <a href="#biomedicines-10-01321-t002" class="usa-link">Table 2</a>.</p>
<section class="tw xbox font-sm" id="biomedicines-10-01321-t002"><h5 class="obj_head">Table 2.</h5>
<div class="caption p"><p>Genetic panel for bioinformatics analysis.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups"><tbody>
<tr>
<td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">TP53</td>
<td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">PIK3CA</td>
<td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">mTOR</td>
<td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">FOXA1</td>
<td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">FOXO1</td>
<td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">BRCA1</td>
<td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">BRCA2</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PTEN</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CREB</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AR</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ETV1</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ETV3</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ETV4</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ETV6</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ALDH1A1</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ALDH3A1</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SPOP</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FLI1</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IDH1</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ERG</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SOX2</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">cMET (HGFR)</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HGF</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SPARC</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CAV1</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BMI1</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PARP1</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RB1</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ATM</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CHEK2</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EGFR</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">POLE</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">POLD1</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MSH2</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MLH1</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RAD51D</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SYK</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
</tr>
</tbody></table></div>
<div class="p text-right font-secondary"><a href="table/biomedicines-10-01321-t002/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></section><p>Once the DNA libraries were indexed, they were PCR-amplified, quantified, and pooled before hybridization to a custom NimbleGen SeqCap EZ Choice Library (Roche) of oligonucleotide DNA probes that were complementary to the coding sequences of the 37 selected genes (<a href="#biomedicines-10-01321-t002" class="usa-link">Table 2</a>). Regulatory sequences and splicing sites were also included. The pooling strategy was 8 samples per pool. The hybridization was performed over-night for 18 h. After stringent washing, the captured libraries were PCR-amplified and sequenced to generate 2 × 150 bp paired-end reads with a MiSeq platform (Illumina, San Diego, CA, USA). Finally, the resulting DNA sequences were automatically demultiplexed and aligned to the human reference genome Hg19. Sequence variants were detected and annotated by Webannovar.</p>
<p>The thresholds for the candidate variants were 1000× for locus coverage, and 50 total reads (25 reads on both sequenced DNA strands) reporting the variant [<a href="#B44-biomedicines-10-01321" class="usa-link" aria-describedby="B44-biomedicines-10-01321">44</a>].</p>
<p>Common polymorphisms (≥1% in the general population) were discarded by comparison with NCBI, dbSNP, 1000 genomes, and EXAC, and then automatically investigated by Webannovar. However, since these databases contain known disease-associated mutations, all detected variants were compared with the gene-specific mutation databases, ClinVar and COSMIC. Then, we screened for mutations that could give rise to premature protein-truncating mutations or those with a high impact on the protein structure, such as, stop mutations, missense variants, mutations on splice sites, and exonic indels.</p>
<p>Unknown variants were automatically ranked by Webannovar pipeline. This ranking was based upon the evolutionary conservation and potential level of danger of the affected nucleotide locus, using Sift, Polyphen2, Mutation tester, FATHMM, ProVean, MetaSVM, and M-CAP [<a href="#B44-biomedicines-10-01321" class="usa-link" aria-describedby="B44-biomedicines-10-01321">44</a>].</p>
<p>Mutation rates (per megabase) was determined dividing the mutation count for each sample by the extension gene panel (0.1092 Mb).</p></section></section><section id="sec2dot3-biomedicines-10-01321"><h3 class="pmc_sec_title">2.3. Statistical Analysis</h3>
<p>The database was formatted using Microsoft Excel<sup>®</sup> software and later imported from IBM-SPSS<sup>®</sup> software ver. 26.0.1 (IBM SPSS Inc. Chicago, IL, USA). The use of the Stata<sup>®</sup> software ver. 16.0 (Stata Corporation, College Station, TX, USA) was also considered for comparisons or implementations of the test output.</p>
<section id="sec8"><h4 class="pmc_sec_title">Normality of the Distributions as Assessed Using the Kolmogorov–Smirnov Test</h4>
<p>Categorical variables were presented as frequencies or percentages, and compared with the use of the Chi-Square test and the Fisher’s exact test, as appropriate; associations of the crosstabs were verified using standardized adjusted residuals.</p>
<p>Continuous variables were presented as means ± standard deviation (SD) (in the case of a normal distribution), or medians, and min/max (in the case of a skewed distribution) and compared with the use of Student’s T-test, ANOVA, or the Mann–Whitney and Kruskal–Wallis test; correlations among variables were analyzed by the Pearson’s or Spearman’s rank correlation test. A stepwise logistic regression analysis including all variables with probability values &lt; 0.05 in the univariate analysis was used to determine independent predictors; ATM no/yes was the dependent variable, and overall ADT treatment time, FOXA1 yes/no, site of recurrence after primary treatment (nodal, bone or both), local control disease yes/no, BRCA1 yes/no, POLD1 yes/no, were the independent variables. The results are presented as an odds ratio (OR) with 95% confidence intervals. A two-sided α level of 0.05 was used for all tests. The authors had full access to and take full responsibility for the integrity of the data.</p></section></section></section><section id="sec3-biomedicines-10-01321"><h2 class="pmc_sec_title">3. Results</h2>
<section id="sec3dot1-biomedicines-10-01321"><h3 class="pmc_sec_title">3.1. Population Clinical Characteristics and Outcomes</h3>
<p>A total of 28 patients with castrate sensitive, oligorecurrent prostate cancer were considered suitable for this study between November 2017 and July 2018 at the Spedali Civili Hospital of Brescia. The median age was 67 years (52–75). Population characteristics and treatment outcomes are summarized in <a href="#biomedicines-10-01321-t003" class="usa-link">Table 3</a>.</p>
<section class="tw xbox font-sm" id="biomedicines-10-01321-t003"><h4 class="obj_head">Table 3.</h4>
<div class="caption p"><p>Population characteristics.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups"><tbody>
<tr>
<td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<strong>Age</strong>
</td>
<td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">N</td>
<td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">%</td>
<td colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">
<strong>Residual Disease after Surgery</strong>
</td>
<td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">N</td>
<td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">%</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;65 years</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">46.4</td>
<td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">R0 (no)</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">28.6</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">≥65 years</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">53.6</td>
<td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">R1 (microscopic)</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">53.6</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
<td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">R2 (macroscopic)</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.0</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>T stage</strong>
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">%</td>
<td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">T1c</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10.7</td>
<td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<strong>EBRT <sup>1</sup> (total dose)</strong>
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">%</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">T2c</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21.4</td>
<td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">66 Gy</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21.4</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">T3a</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">39.4</td>
<td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">70 Gy</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">64.2</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">T3b</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21.4</td>
<td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">74 Gy</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.6</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">T4</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.1</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
<td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Elective node irradiation</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.1</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>N stage</strong>
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">%</td>
<td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N0</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">85.7</td>
<td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<strong>Adjuvant ADT <sup>1</sup></strong>
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">%</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N1</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14.3</td>
<td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">No</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">75.0</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
<td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">LHRH-analogue</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.1</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>Gleason Grade Group</strong>
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">%</td>
<td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Antiandrogen</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14.3</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21.4</td>
<td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Total Androgen Blockade</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.6</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">39.4</td>
<td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10.7</td>
<td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<strong>Biochemical relapse after primary treatment</strong>
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">%</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.1</td>
<td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Yes</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">27</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">96.4</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21.4</td>
<td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">No</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.6</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>D’Amico Risk Class</strong>
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">%</td>
<td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<strong>Biochemical control duration</strong>
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">%</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Very low</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0,0</td>
<td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">&lt;1 year</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17.9</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Low</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.1</td>
<td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">1–5 years</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">53.6</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Favorable intermediate</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14.3</td>
<td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">&gt;5 years</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">28.5</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Unfavorable intermediate</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.1</td>
<td colspan="3" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Median bRFS<sup>1</sup> 42.4mo (range 1.9–133.1)</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">42.9</td>
<td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Very high</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">28.6</td>
<td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<strong>ADT <sup>1</sup> for biochemical relapse</strong>
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">%</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
<td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">No relapse</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.6</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>Primary treatment</strong>
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">%</td>
<td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">No</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">60.7</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Surgery</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.6</td>
<td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">LHRH-analogue</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21.4</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EBRT <sup>1</sup>
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10.7</td>
<td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Antiandrogen</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10.7</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Brachytherapy<br>(LDR 145 Gy)</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.1</td>
<td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Total Androgen Blockade</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.6</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Surgery+Adjuvant RT <sup>1</sup>
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">32.2</td>
<td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Surgery+Salvage RT <sup>1</sup>
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">46.4</td>
<td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<strong>Number of treated lymph nodes</strong>
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">%</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
<td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">1 lymph node</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50.0</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>Oligorecurrence site</strong>
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">%</td>
<td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">2 lymph nodes</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17.8</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nodal</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">71.5</td>
<td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">3 lymph nodes</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.1</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bone</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21.4</td>
<td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">4 lymph nodes</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.6</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Both</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.1</td>
<td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
<td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<strong>Bone SBRT <sup>1</sup> target</strong>
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">%</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>Nodal SBRT <sup>1</sup> target</strong>
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">%</td>
<td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Axial</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14.3</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pelvic lymph nodes</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">67.8</td>
<td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Extra-axial</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14.3</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Abdominal lymph nodes</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.1</td>
<td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Hip</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10.7</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Both</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.6</td>
<td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Sternum/Ribs</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.1</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">One nodal region</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">64.2</td>
<td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">One site</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21.4</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">More than one nodal region</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14.3</td>
<td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Two sites</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.1</td>
</tr>
</tbody></table></div>
<div class="p text-right font-secondary"><a href="table/biomedicines-10-01321-t003/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="fn4"><p><sup>1</sup> EBRT = External-Beam Radiation Therapy; LDR = Low Dose Rate; RT = Radiation Therapy; SBRT = Stereotactic Body. Radiation Therapy; ADT = Androgen Deprivation Therapy; bRFS = biochemical Relapse-Free Survival.</p></div></div></section><p>All of the treated lesions were detected by 11C-Choline PET-TC, then used to support radiation treatment planning. Nodal metastases were recorded in 20 (71.5%) patients, while 6 (21.4%) of them had bone lesions; both nodal and bone involvement were reported in 2 (7.1%) cases.</p>
<p>At the end of the observation period, a median follow-up of 34.9 months (range 17.4–43.7) was reported. We recorded an 83% local control of disease after the first SBRT; grade 1 acute bladder toxicity in 1 case; grade 2 late bowel toxicity; no grade ≥ 3 acute or late toxicity. The median ADT-free survival was 19.5 months (range 5.5–43.9).</p></section><section id="sec3dot2-biomedicines-10-01321"><h3 class="pmc_sec_title">3.2. Genomic Landscape of Oligometastatic Prostate Cancer</h3>
<p>Blood samples were collected from all patients before radiation treatment and approximately 2.5 mL of serum were processed for cfDNA. The median [cfDNA] was 30.2 ng/mL (range 4.2–171.6 ng/mL) (<a href="#biomedicines-10-01321-f001" class="usa-link">Figure 1</a>).</p>
<figure class="fig xbox font-sm" id="biomedicines-10-01321-f001"><h4 class="obj_head">Figure 1.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=9219949_biomedicines-10-01321-g001.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db03/9219949/af1ffec1c370/biomedicines-10-01321-g001.jpg" loading="lazy" height="452" width="778" alt="Figure 1"></a></p>
<div class="p text-right font-secondary"><a href="figure/biomedicines-10-01321-f001/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Serum cfDNA concentration (ng/mL) in oligometastatic prostate cancer patients.</p></figcaption></figure><p>Deep targeted DNA sequencing of 37 prostate cancer relevant genes was performed, and a total of 77 mutations were detected in 25 of 28 cfDNA samples (<a href="#biomedicines-10-01321-f002" class="usa-link">Figure 2</a>). A detailed list of the detected mutations is reported in <a href="#app2-biomedicines-10-01321" class="usa-link">Appendix B</a>, <a href="#biomedicines-10-01321-t0A2" class="usa-link">Table A2</a>.</p>
<figure class="fig xbox font-sm" id="biomedicines-10-01321-f002"><h4 class="obj_head">Figure 2.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=9219949_biomedicines-10-01321-g002.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db03/9219949/17b535c201f9/biomedicines-10-01321-g002.jpg" loading="lazy" height="534" width="778" alt="Figure 2"></a></p>
<div class="p text-right font-secondary"><a href="figure/biomedicines-10-01321-f002/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Genomic landscape of oligometastatic prostate cancer from targeted serum cfDNA sequencing. Oncoprint shows genomic alterations identified in cfDNA of patients with oligometastatic prostate cancer. Genes are grouped by pathway (37 genes shown). Mutational frequency for each gene in the targeted panel is provided on the right.</p></figcaption></figure><p>The median tumor mutational load was 27.5/Mb (range, 0–73.3 mutations/Mb) (<a href="#biomedicines-10-01321-f003" class="usa-link">Figure 3</a>).</p>
<figure class="fig xbox font-sm" id="biomedicines-10-01321-f003"><h4 class="obj_head">Figure 3.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=9219949_biomedicines-10-01321-g003.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db03/9219949/d792e04918d6/biomedicines-10-01321-g003.jpg" loading="lazy" height="305" width="756" alt="Figure 3"></a></p>
<div class="p text-right font-secondary"><a href="figure/biomedicines-10-01321-f003/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Mutation rate of oligometastatic prostate cancer patients.</p></figcaption></figure><p>Genomic alterations mainly occurred in the AR and DNA repair gene pathways. Nine different deletions, two insertions, and one missense mutation regarding AR genes were identified in 13 (46.4%) patients. Among these, four (30.8%) patients carried the 171_176 deletions and two (15.4%) others, the 171_182 deletion. Furthermore, alterations in the FOXA1 gene were detected (3 (10.7%) cases). ATM mutations were identified in 14 (50.0%) patients in the cohort, and most of them were missense mutations. Intriguingly, six (42.9%) patients harbored the 5557 G &gt; A mutation, two (14.3%) of them carried the 3161 G &gt; C mutation, one (7.1%) patient had a stopgain mutation, and one (7.1%) a frameshift deletion. We observed frameshift deletions and missense mutations in BRCA2 in 11 (39.3%) patients, eight of whom (72.7%) harbored the 1114 C &gt; A aberration. Patient 08 carried a frameshift deletion in the BRCA2 gene, causing a truncated protein product. Six (21.4%) patients showed missense mutations in th BRCA1 sequence, and three (50.0%) of them harbored the 1936 A &gt; G aberration. POLE mutations were identified in five (17.9%) patients, four (80.0%) of them showing the 755 C &gt; T mutation. Four (14.3%) patients carried a 158 G &gt; A alteration in the RAD51D gene, and one (3.6%) patient harbored a missense mutation in MSH2. A loss of heterozygosis was also observed: two patients harboring the 1114 C &gt; A BRCA2 alteration, one patient carrying the 1936A &gt; G BRCA1 mutation, and one patient with the 158A &gt; G RAD51D variant. Missense mutations in HGF were also observed (three (10.7%) cases). Four (14.3%) patients carried ETS gene fusion variants: two (7.1%) patients with missense mutations in ETV4, and two (7.1%) patients with a missense mutation and a stopgain mutation, respectively. Finally, missense mutations in the IDH1 (one (3.6%) patient), ALDH1A1 (one (3.6%)), and SPARC (one (3.6%)) stemness genes were identified. We did not observe mutations in the PI3KCA pathway, nor in tumor suppressor genes. </p>
<p>When analyzing the interaction between the identified genomic alterations and pre-treatment [cfDNA], we found a lower median [cfDNA] in ETV4 carriers than in ETV4 non-carriers (6.6 ng/mL and 33.35 ng/mL, respectively) (<em>p</em> = 0.021), together with a lower median [cfDNA] in ATM carriers than ATM non-carriers (24.02 ng/mL and 40.035 ng/mL, respectively) (<em>p</em> = 0.039).</p>
<p>The interaction between the identified genomic alterations and clinical parameters was also investigated. There was a trend for an increased risk for ADT prescription requirement in ATM mutation carriers (OR = 0.160, <em>p</em> = 0.057), while SBRT failure was associated with an increased risk of harboring BRCA1 mutations (OR = 10.5, <em>p</em> = 0.043).</p></section></section><section id="sec4-biomedicines-10-01321"><h2 class="pmc_sec_title">4. Discussion</h2>
<p>Metastatic prostate cancer has been demonstrated to be molecularly heterogeneous, with clinical heterogeneous behavior [<a href="#B45-biomedicines-10-01321" class="usa-link" aria-describedby="B45-biomedicines-10-01321">45</a>,<a href="#B46-biomedicines-10-01321" class="usa-link" aria-describedby="B46-biomedicines-10-01321">46</a>]. To date, many treatment options are available for the management of metastatic prostate cancer; nevertheless, there are some unmet needs for patient stratification in this setting [<a href="#B47-biomedicines-10-01321" class="usa-link" aria-describedby="B47-biomedicines-10-01321">47</a>]. In this scenario, biomarker discovery using liquid biopsy has become an interesting field of study [<a href="#B37-biomedicines-10-01321" class="usa-link" aria-describedby="B37-biomedicines-10-01321">37</a>,<a href="#B48-biomedicines-10-01321" class="usa-link" aria-describedby="B48-biomedicines-10-01321">48</a>]. There is a growing interest for deep targeted cfDNA sequencing as a promising way of identifying evolution markers underlying progressive cancer or the metastases process before clinical onset [<a href="#B37-biomedicines-10-01321" class="usa-link" aria-describedby="B37-biomedicines-10-01321">37</a>]. DNA sequencing approaches based on next-generation (NGS) technology have enabled the rapid, high-quality analysis of genes that may be relevant for disease-specific characterization. NGS can generate wide and complete masses of DNA sequence data, and perform quick and cost-effective genetic analysis [<a href="#B38-biomedicines-10-01321" class="usa-link" aria-describedby="B38-biomedicines-10-01321">38</a>]. Currently, there is only one Food and Drug Administration (FDA)-approved liquid biopsy assay for the detection of BRCA1, BRCA2, and/or ATM aberrations in patients with metastatic castrate-resistant prostate cancer (mCRPC) who may be appropriate for the treatment with poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi) [<a href="#B49-biomedicines-10-01321" class="usa-link" aria-describedby="B49-biomedicines-10-01321">49</a>,<a href="#B50-biomedicines-10-01321" class="usa-link" aria-describedby="B50-biomedicines-10-01321">50</a>]. Compared to tissue biopsy, liquid biopsy is non-invasive and captures aggregate features from tumor material-releasing metastases, thus providing real-time information on the state of the disease. It may be a useful tool for treatment resistance tracking [<a href="#B37-biomedicines-10-01321" class="usa-link" aria-describedby="B37-biomedicines-10-01321">37</a>,<a href="#B48-biomedicines-10-01321" class="usa-link" aria-describedby="B48-biomedicines-10-01321">48</a>,<a href="#B51-biomedicines-10-01321" class="usa-link" aria-describedby="B51-biomedicines-10-01321">51</a>].</p>
<p>OPC represents a phenotype with limited metastatic potential, and reveals heterogeneity in clinical behavior [<a href="#B1-biomedicines-10-01321" class="usa-link" aria-describedby="B1-biomedicines-10-01321">1</a>,<a href="#B4-biomedicines-10-01321" class="usa-link" aria-describedby="B4-biomedicines-10-01321">4</a>]. Metastases-directed, ablative SBRT has been gaining validation as a safe and effective treatment option for oligorecurrent/oligoprogressive PC [<a href="#B52-biomedicines-10-01321" class="usa-link" aria-describedby="B52-biomedicines-10-01321">52</a>]. Beyond the large number of promising findings from retrospective data, the prospective, phase II Observation versus stereotactic ablative RadiatIon for OLigometastatic Prostate CancEr Trial (ORIOLE) recently confirmed SBRT to improve oncologic outcomes in a certain setting of oligometastatic PC patients, with an excellent local control of disease and mild adverse events, with no impact on the patient quality of life [<a href="#B33-biomedicines-10-01321" class="usa-link" aria-describedby="B33-biomedicines-10-01321">33</a>]. Preliminary results from the randomized, phase II Surveillance or metastasis-directed Therapy for OligoMetastatic Prostate cancer recurrence (STOMP) trial also supported the utility of metastasis-directed therapy (surgery or SBRT) in the oligometastatic state of PC [<a href="#B31-biomedicines-10-01321" class="usa-link" aria-describedby="B31-biomedicines-10-01321">31</a>,<a href="#B32-biomedicines-10-01321" class="usa-link" aria-describedby="B32-biomedicines-10-01321">32</a>].</p>
<p>Despite the excellent local control and improved survival obtained with such a metastasis-directed treatment approach (i.e., surgery or ablative SBRT), sometimes OPC only represents the initial step of a rapid, unavoidable progression to a polymetastatic disease [<a href="#B7-biomedicines-10-01321" class="usa-link" aria-describedby="B7-biomedicines-10-01321">7</a>]. The identification of features that discriminate a true oligometastatic state and a polymetastatic progression phenotype is challenging. Since the nucleic acids released into the blood stream are considered to be cell messengers, information regarding a true oligometastatic condition and/or tumor cell reactions to radiation may be derived [<a href="#B53-biomedicines-10-01321" class="usa-link" aria-describedby="B53-biomedicines-10-01321">53</a>]. However, unlike colorectal or lung cancer, there are no recurrent point mutations in PC that can be used to track the disease. Moreover, relevant to intra-patient heterogeneous diseases, different sites of metastases may likely have different DNA release rates, and the ability to detect cfDNA-based features is gene region- and individual dependent [<a href="#B54-biomedicines-10-01321" class="usa-link" aria-describedby="B54-biomedicines-10-01321">54</a>,<a href="#B55-biomedicines-10-01321" class="usa-link" aria-describedby="B55-biomedicines-10-01321">55</a>,<a href="#B56-biomedicines-10-01321" class="usa-link" aria-describedby="B56-biomedicines-10-01321">56</a>,<a href="#B57-biomedicines-10-01321" class="usa-link" aria-describedby="B57-biomedicines-10-01321">57</a>].</p>
<p>We planned a prospective, pilot study since there are no similar biological study designs to compare with for accrual evaluation that have ever been reported in the literature.</p>
<p>The primary endpoints were differences in molecular contribution between the oligometastatic and polymetastatic evolution of prostate cancer to same-first oligorecurrent disease presentation, and their association with ADT-free survival (ADT-FS), defined as the time between the first day of SBRT and the start of palliative ADT. The secondary endpoints were: distant progression-free survival (DPFS, defined as the time between the first day of SBRT and the detection of clinical disease outside the PTV after further biochemical progression); local control (in-field control) of disease (defined as no evidence of disease in the treatment field at the restaging Choline- or PSMA-PET/CT).</p>
<p>Our exploratory analysis revealed that cfDNA concentrations in patients with OPC were relatively low, considering those reported in literature for patients with mCRPC, which is a more advanced and prognostically unfavorable stage of the disease [<a href="#B58-biomedicines-10-01321" class="usa-link" aria-describedby="B58-biomedicines-10-01321">58</a>]. Despite the absence of a direct comparison between the two groups in our study, nor in the available literature, taking into account the current biological evidence regarding cancer metastatization [<a href="#B2-biomedicines-10-01321" class="usa-link" aria-describedby="B2-biomedicines-10-01321">2</a>,<a href="#B3-biomedicines-10-01321" class="usa-link" aria-describedby="B3-biomedicines-10-01321">3</a>], we may hypothesize that such lower cfDNA concentration is likely to reflect the limited metastatic potential of the oligometastatic state [<a href="#B58-biomedicines-10-01321" class="usa-link" aria-describedby="B58-biomedicines-10-01321">58</a>].</p>
<p>The distribution of the genomic alterations in our study were highly consistent with the genomic landscape of prostate cancer described in literature [<a href="#B45-biomedicines-10-01321" class="usa-link" aria-describedby="B45-biomedicines-10-01321">45</a>,<a href="#B46-biomedicines-10-01321" class="usa-link" aria-describedby="B46-biomedicines-10-01321">46</a>]. As expected, mutations in the AR and DNA repair genes included in our panel were the most common ones, in particular, the ATM and BRCA1/BRCA2 genes, and they seemed to drive high tumor mutation load and rapid polymetastatic spread after the first oligorecurrence treated with SBRT. In detail, most of the AR aberrations consisted of non-frameshift deletions, and they were located in a possible critical and hotspot region of the N-terminal domain of the receptor. We did not observe mutations in the ligand-binding domain, as is commonly mapped [<a href="#B59-biomedicines-10-01321" class="usa-link" aria-describedby="B59-biomedicines-10-01321">59</a>]. BRCA1/2 and ATM aberrations have been reported to be associated with a more aggressive prostate cancer phenotype, with an increased risk of disease recurrence and poorer survival outcomes [<a href="#B60-biomedicines-10-01321" class="usa-link" aria-describedby="B60-biomedicines-10-01321">60</a>,<a href="#B61-biomedicines-10-01321" class="usa-link" aria-describedby="B61-biomedicines-10-01321">61</a>,<a href="#B62-biomedicines-10-01321" class="usa-link" aria-describedby="B62-biomedicines-10-01321">62</a>]. In our cohort, the ATM 3161 G &gt; C variant was associated with an increased prostate cancer risk [<a href="#B63-biomedicines-10-01321" class="usa-link" aria-describedby="B63-biomedicines-10-01321">63</a>]. Our findings also showed that the BRCA2 mutation rate was higher than BRCA1, in line with the available literature. BRCA2 mutations are known to be associated with a higher prostate cancer mortality, likely due to the direct involvement of BRCA2 in the homologous recombination process, as it mediates the recruitment of RAD51 to DNA double-strand breaks [<a href="#B61-biomedicines-10-01321" class="usa-link" aria-describedby="B61-biomedicines-10-01321">61</a>]. Of note, although not clearly statistically significant, patients in our series with a history of ADT prescription before metastatic onset (concurrent to primary or salvage treatment) were more likely to have an ATM mutation. However, there are not enough elements to establish whether these are germinal mutations probably harboring a poorer prognosis, or somatic alterations induced by ADT itself. Not less important, OPC patients with combined mismatch repair gene and BRCA2 mutations seemed to have a worse prognosis. Nearly half of BRCA1-mutated OPC patients also showed no local control of the disease after the first SBRT course. All this being considered, our preliminary data suggested that the presence of high-risk prostate cancer mutations (regarding ATM, BRCA1, and BRCA2 genes) might be the starting point for identifying a subset of patients who may benefit from systemic treatment and local radiotherapy in combination strategies since the first clinical and radiological evidence of metastatic, castrate-sensitive PC.</p>
<p>In the near future, the PC oligometastatic state should be better characterized based on its molecular features, not only considering the number of metastatic lesions [<a href="#B1-biomedicines-10-01321" class="usa-link" aria-describedby="B1-biomedicines-10-01321">1</a>,<a href="#B6-biomedicines-10-01321" class="usa-link" aria-describedby="B6-biomedicines-10-01321">6</a>,<a href="#B64-biomedicines-10-01321" class="usa-link" aria-describedby="B64-biomedicines-10-01321">64</a>].</p>
<p>To our knowledge, our series may be considered the first prospective one with translational implications in the field of oligometastatic PC.</p>
<p>Unfortunately, the relatively small sample size of our study is the main limitation of our study, and it did not allow much powerful conclusions to be drawn. However, our prospective pilot study provided some promising clinical insights regarding the possible identification of metastatic prostate cancer evolution markers. Whether our results were confirmed for a wider cohort of patients, it would be possible to set up gene clustering for a highly accurate prognostic stratification of patients with metastatic PC.</p>
<p>Tracking molecular evolution markers predictive for a better response to stereotactic irradiation, or for a worse prognosis, which supports the need for systemic therapy, may offer some clues for defining the best radiation treatment features and technological solutions in the rapidly expanding field of stereotactic cancer treatments. Of note, the identification of a true oligometastatic state that is amenable to local, ablative treatment may also allow for the postponement of the need for ADT in a significant number of patients, ensure better patient QoL, a reduction in possible side effects (i.e., metabolic syndrome, climacteric syndrome, etc.) and reduced healthcare costs.</p></section><section id="sec5-biomedicines-10-01321"><h2 class="pmc_sec_title">5. Conclusions</h2>
<p>We proposed a preliminary, exploratory analysis of serum-derived cfDNA samples collected before SBRT treatment through a deep target sequencing approach. We investigated whether the sequencing of 37 prostate cancer-relevant genes might contribute to the recognition of the heterogeneity of oligometastatic prostate disease, and a better molecular characterization of oligometastatic disease. Moreover, we attempted to examine the obtained molecular data, to predict an eventual polymetastatic progression.</p>
<p>Our study may represent a crucial foundation for the future design of clinical trials owing to provide the stratification of patients with OPC based on a molecular signature. Moreover, the assessment of a molecular fingerprint for OPC may allow for the identification of patients with a true oligometastatic phenotype, and hence, with stable disease for a long time, which are more likely to benefit from local, curative treatments, or the achievement of long-term disease control. The prospective validation of our promising findings on a wider series is desirable for a better understanding of the real impact of liquid biopsy analysis in detecting tumor features. Whether our findings were confirmed on a large scale, liquid biopsy might become a useful source of prognostic and predictive markers of metastatic prostate cancer spread. The real-time molecular characterization of cancer disease by liquid biopsy is also expected to be crucial for setting a patient-tailored therapeutic approach based on tumor aggressiveness and clonal evolution, to be applied a long time before clinical onset and the subsequent clinical appearance of advanced and extended progression of disease.</p></section><section id="ack1" class="ack"><h2 class="pmc_sec_title">Acknowledgments</h2>
<p>The authors acknowledge Milena Tartarelli for data management, administrative support, and management of relations with the Ethics Committee.</p></section><section id="app1-biomedicines-10-01321" class="app"><h2 class="pmc_sec_title">Appendix A</h2>
<section id="secAdot1-biomedicines-10-01321"><h3 class="pmc_sec_title">Appendix A.1. Radiotherapy Procedures</h3>
<section id="secAdot1dot1-biomedicines-10-01321"><h4 class="pmc_sec_title">Appendix A.1.1. Target Volume Delineation</h4>
<p>A CT-based treatment planning with slice thicknesses of 2–3 mm was performed. Then, target volume delineation by co-registration of the planning CT images with the available morphological and functional images was applied.</p>
<p>The gross tumor volume (GTV) was defined by imaging co-registration between the simulation CT scan and the restaging CT-PET. Then, an isotropic additional margin of 6 mm was applied to the GTV to obtain the Planning Tumor Volume (PTV). In the case of upper abdominal lesions, 4D-CT was used to define the internal target volume (ITV), and the PTV was defined as a 6 mm isotropic expansion from the ITV. The target volume delineation and dose delivery calculation were performed using Pinnacle Treatment Planning System (Pinnacle TPS, Philips Radiation Oncology Systems, Fitchburg, WI, USA).</p></section><section id="secAdot1dot2-biomedicines-10-01321"><h4 class="pmc_sec_title">Appendix A.1.2. Dose Prescription</h4>
<p>All patients underwent stereotactic body radiation therapy (SBRT) with image-guided, helical, or volumetric intensity-modulated radiation therapy (IMRT-IGRT). A course of 36 Gy–6 Gy/fraction (fx) was prescribed on nodal lesions, and 30 Gy–10 Gy/fx on bone lesions (36 Gy–6 Gy/fx when the previous schedule was not applicable), with a corresponding tumor biological effective dose (BED) of 144 Gy and an equivalent dose of 2 Gy (EQD2) 72 Gy in the former, with BED 180 Gy–EQD2 90 Gy in the latter (considering α/ß 1.5 Gy).</p></section><section id="secAdot1dot3-biomedicines-10-01321"><h4 class="pmc_sec_title">Appendix A.1.3. Radiotherapy Planning</h4>
<p>Radiotherapy planning was performed, combining an accurate dosimetric and radiobiological evaluation, based on the available literature [<a href="#B9-biomedicines-10-01321" class="usa-link" aria-describedby="B9-biomedicines-10-01321">9</a>,<a href="#B10-biomedicines-10-01321" class="usa-link" aria-describedby="B10-biomedicines-10-01321">10</a>,<a href="#B13-biomedicines-10-01321" class="usa-link" aria-describedby="B13-biomedicines-10-01321">13</a>,<a href="#B14-biomedicines-10-01321" class="usa-link" aria-describedby="B14-biomedicines-10-01321">14</a>,<a href="#B15-biomedicines-10-01321" class="usa-link" aria-describedby="B15-biomedicines-10-01321">15</a>,<a href="#B65-biomedicines-10-01321" class="usa-link" aria-describedby="B65-biomedicines-10-01321">65</a>,<a href="#B66-biomedicines-10-01321" class="usa-link" aria-describedby="B66-biomedicines-10-01321">66</a>,<a href="#B67-biomedicines-10-01321" class="usa-link" aria-describedby="B67-biomedicines-10-01321">67</a>,<a href="#B68-biomedicines-10-01321" class="usa-link" aria-describedby="B68-biomedicines-10-01321">68</a>,<a href="#B69-biomedicines-10-01321" class="usa-link" aria-describedby="B69-biomedicines-10-01321">69</a>,<a href="#B70-biomedicines-10-01321" class="usa-link" aria-describedby="B70-biomedicines-10-01321">70</a>]. Large inhomogeneity in dose distribution was allowed to obtain higher maximal doses within the GTV/ITV, but 95% of PTV was required to be covered by the prescribed dose. The maximum acceptable dose (Dmax) in the PTV was 115% of the prescribed dose (<a href="#biomedicines-10-01321-f0A1" class="usa-link">Figure A1</a>).</p>
<figure class="fig xbox font-sm" id="biomedicines-10-01321-f0A1"><h5 class="obj_head">Figure A1.</h5>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=9219949_biomedicines-10-01321-g0A1.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db03/9219949/5d91bcd8e139/biomedicines-10-01321-g0A1.jpg" loading="lazy" height="220" width="715" alt="Figure A1"></a></p>
<div class="p text-right font-secondary"><a href="figure/biomedicines-10-01321-f0A1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Dose distribution for nodal (<strong>A</strong>) and bone (<strong>B</strong>) SBRT.</p></figcaption></figure><p>Normal tissue dose constraints were as per the Task Group 101 and UK Consensus [<a href="#B67-biomedicines-10-01321" class="usa-link" aria-describedby="B67-biomedicines-10-01321">67</a>,<a href="#B71-biomedicines-10-01321" class="usa-link" aria-describedby="B71-biomedicines-10-01321">71</a>]. These also were the basis for the normal tissue tolerance calculation in 36 Gy in the 6 fx schedule. If normal tissue constraints were beyond tolerance, a 90% PTV coverage was accepted for 30 Gy in the 3 fx schedule, as long as the full coverage of GTV/ITV (≥100% of the prescribed dose) was guaranteed. The reference organs at risk (OAR) dose constraints are reported in <a href="#biomedicines-10-01321-t0A1" class="usa-link">Table A1</a>.</p>
<section class="tw xbox font-sm" id="biomedicines-10-01321-t0A1"><h5 class="obj_head">Table A1.</h5>
<div class="caption p"><p>OAR dose constraints for nodal/bone SBRT.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups"><tbody>
<tr>
<td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<strong>Abdominal targets</strong>
</td>
<td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<strong>Value</strong>
</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">Spine</td>
<td align="center" valign="middle" rowspan="1" colspan="1">Dmax &lt; 18 Gy</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">Kidneys</td>
<td align="center" valign="middle" rowspan="1" colspan="1">V15Gy &lt; 35%</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">Stomach</td>
<td align="center" valign="middle" rowspan="1" colspan="1">V36Gy &lt; 3%,</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">Duodenum</td>
<td align="center" valign="middle" rowspan="1" colspan="1">V36Gy &lt; 1%</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">Bowel bag</td>
<td align="center" valign="middle" rowspan="1" colspan="1">V36Gy &lt; 3%</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Liver</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">V15Gy &lt; critical volume (700 cc)</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>Pelvic targets</strong>
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">Bowel bag</td>
<td align="center" valign="middle" rowspan="1" colspan="1">D1cc &lt; 21 Gy</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">Rectum</td>
<td align="center" valign="middle" rowspan="1" colspan="1">Dmax &lt; 100% of prescription dose</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bladder/Urethra</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dmax &lt; 120% of prescription dose</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>Bone targets</strong>
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">Spine</td>
<td align="center" valign="middle" rowspan="1" colspan="1">Dmax &lt; 21.9 Gy</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">D0.035cc &lt; 18 Gy</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">D1-2cc 12.3 Gy</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">Spinal nerve roots</td>
<td align="center" valign="middle" rowspan="1" colspan="1">D3cc &lt; 20.4 Gy</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">D0.035cc &lt; 24 Gy</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">Descending aorta</td>
<td align="center" valign="middle" rowspan="1" colspan="1">Dmax &lt; 30 Gy</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">Ileum</td>
<td align="center" valign="middle" rowspan="1" colspan="1">Dmax &lt; 25.2 Gy</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Spine</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">D5cc &lt; 17.7 Gy</td>
</tr>
</tbody></table></div>
<div class="p text-right font-secondary"><a href="table/biomedicines-10-01321-t0A1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></section></section><section id="secAdot1dot4-biomedicines-10-01321"><h4 class="pmc_sec_title">Appendix A.1.4. Follow Up</h4>
<p>Following SBRT, patients commenced clinical follow up (FU): clinical examination and PSA detection every 3 months for the first year, then every 6 months until progression of disease (PD); interview for PC-related symptoms, gastrointestinal (GI) and genitourinary (GU) toxicity (according to CT-CAE classification—v4.02 [<a href="#B72-biomedicines-10-01321" class="usa-link" aria-describedby="B72-biomedicines-10-01321">72</a>]) every 3 months for the first year, then every 6 months until PD. In the case of biochemical progression, restaging with 11C-Choline/68Ga-PSMA PET was required. For the purpose of the present protocol, data collection continued for a planned observation period of 36 months after the treatment of OPC.</p></section></section></section><section id="app2-biomedicines-10-01321" class="app"><h2 class="pmc_sec_title">Appendix B</h2>
<section class="tw xbox font-sm" id="biomedicines-10-01321-t0A2"><h3 class="obj_head">Table A2.</h3>
<div class="caption p"><p>List of the 77 detected mutations from the DNA sequencing of 37 prostate cancer-relevant genes (nucleotide aberrations).</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Sample</th>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Chromosome</th>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Start</th>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">End</th>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reference Nucleotide</th>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Altered<br>Nucleotide</th>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Gene</th>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Effect</th>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Evolution<br>Disease</th>
</tr></thead>
<tbody>
<tr>
<td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">1</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">chr11</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">108272729</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">108272729</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">G</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ATM</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">missense</td>
<td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Polymetastatic disease</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">chrX</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">67545317</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">67545319</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GCA</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AR</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">nonframeshift deletion</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">chr2</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">47512394</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">47512394</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">G</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MSH2</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">missense</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oligometastatic disease</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">chr11</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">108249096</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">108249096</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">T</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ATM</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">missense</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Polymetastatic disease</td>
</tr>
<tr>
<td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">4</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">chr11</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">108310287</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">108310287</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">G</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ATM</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">missense</td>
<td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Oligometastatic disease</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">chr14</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">37594904</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">37594904</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">G</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FOXA1</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">missense</td>
</tr>
<tr>
<td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">5</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">chr5</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">151663550</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">151663550</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">T</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SPARC</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">missense</td>
<td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Oligometastatic disease</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">chr11</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">108249096</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">108249096</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">T</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ATM</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">missense</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">chr12</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11891545</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11891545</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">T</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ETV6</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">UTR3</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">chrX</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">67546515</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">67546529</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GGCGGCGGCGGCGGC</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AR</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">nonframeshift deletion</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">chrX</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">67546518</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">67546529</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GGCGGCGGCGGC</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AR</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">nonframeshift deletion</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oligometastatic disease</td>
</tr>
<tr>
<td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">7</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">chr2</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">208243577</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">208243577</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">G</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IDH1</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">missense</td>
<td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Oligometastatic disease</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">chr17</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">43074471</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">43074471</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">G</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">T</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BRCA1</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">missense</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">chrX</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">67545316</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">67545316</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GCA</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AR</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">nonframeshift insertion</td>
</tr>
<tr>
<td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">8</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">chr9</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">72952984</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">72952984</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">T</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ALDH1A1</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">missense</td>
<td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Oligometastatic disease</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">chr13</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">32329468</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">32329469</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TG</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BRCA2</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">frameshift deletion</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">chr13</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">32340099</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">32340099</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">T</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BRCA2</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">missense</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">chrX</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">67545317</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">67545322</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GCAGCA</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AR</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">nonframeshift deletion</td>
</tr>
<tr>
<td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">9</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">chr11</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">108244873</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">108244873</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">T</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ATM</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">stopgain</td>
<td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Oligometastatic disease</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">chr12</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11890993</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11890993</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">G</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ETV6</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">missense</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">chr13</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">32332592</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">32332592</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BRCA2</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">missense</td>
</tr>
<tr>
<td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">10</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">chr14</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">37591441</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">37591441</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">G</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FOXA1</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">missense</td>
<td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Polymetastatic disease</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">chr17</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">35106468</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">35106468</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">G</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RAD51D</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">missense</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">chrX</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">67545317</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">67545322</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GCAGCA</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AR</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">nonframeshift deletion</td>
</tr>
<tr>
<td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">11</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">chr13</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">32332592</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">32332592</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BRCA2</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">missense</td>
<td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Polymetastatic disease</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">chr17</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">43092412</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">43092412</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">G</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BRCA1</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">missense</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">chr19</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50413766</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50413766</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">G</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">POLD1</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">missense</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oligometastatic disease</td>
</tr>
<tr>
<td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">13</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">chr7</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">81745064</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">81745064</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">T</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">G</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HGF</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">missense</td>
<td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Polymetastatic disease</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">chr11</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">108272849</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">108272849</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">G</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ATM</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">missense</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">chr11</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">108304735</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">108304735</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">G</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ATM</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">missense</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">chr13</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">32338416</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">32338416</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">T</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BRCA2</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">missense</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">chrX</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">67545317</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">67545328</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GCAGCAGCAGCA</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AR</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">nonframeshift deletion</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Polymetastatic disease</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">chr11</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">108304735</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">108304735</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">G</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ATM</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">missense</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Polymetastatic disease</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">chr14</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">37592342</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">37592342</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">G</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FOXA1</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">missense</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oligometastatic disease</td>
</tr>
<tr>
<td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">17</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">chr11</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">108289623</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">108289623</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">T</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ATM</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">missense</td>
<td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Oligometastatic disease</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">chr11</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">108279497</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">108279497</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ATM</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">frameshift deletion</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">chr13</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">32332592</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">32332592</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BRCA2</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">missense</td>
</tr>
<tr>
<td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">18</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">chr12</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">132677409</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">132677409</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">T</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">POLE</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">missense</td>
<td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Polymetastatic disease</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">chr7</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">81729735</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">81729735</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">G</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HGF</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">missense</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">chr17</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">43093454</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">43093454</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">G</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BRCA1</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">missense</td>
</tr>
<tr>
<td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">19</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">chr13</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">32332592</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">32332592</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BRCA2</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">missense</td>
<td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Oligometastatic disease</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">chr17</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">35106468</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">35106468</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">G</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RAD51D</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">missense</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">chrX</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">67545317</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">67545322</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GCAGCA</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AR</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">nonframeshift deletion</td>
</tr>
<tr>
<td rowspan="8" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">20</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">chr11</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">108272729</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">108272729</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">G</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ATM</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">missense</td>
<td rowspan="8" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Oligometastatic disease</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">chr11</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">108267276</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">108267276</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">T</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ATM</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">missense</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">chr12</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">132677409</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">132677409</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">T</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">POLE</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">missense</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">chr13</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">32332592</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">32332592</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BRCA2</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">missense</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">chr17</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">43093454</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">43093454</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">G</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BRCA1</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">missense</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">chr17</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">35106468</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">35106468</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">G</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RAD51D</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">missense</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">chrX</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">67546514</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">67546514</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GGC</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AR</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">nonframeshift insertion</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">chrX</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">67545319</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">67545319</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">T</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AR</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">missense</td>
</tr>
<tr>
<td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">21</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">chr7</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">81729735</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">81729735</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">G</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HGF</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">missense</td>
<td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Oligometastatic disease</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">chr12</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">132676174</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">132676174</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">T</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">G</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">POLE</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">missense</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">chr13</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">32332592</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">32332592</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BRCA2</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">missense</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">chrX</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">67545317</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">67545325</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GCAGCAGCA</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AR</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">nonframeshift deletion</td>
</tr>
<tr>
<td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">22</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">chr11</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">108304735</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">108304735</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">G</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ATM</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">missense</td>
<td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Oligometastatic disease</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">chr12</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">132677409</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">132677409</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">T</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">POLE</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">missense</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">chr17</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">43070958</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">43070958</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">G</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BRCA1</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">missense</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">chr17</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">35106468</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">35106468</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">G</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RAD51D</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">missense</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">chrX</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">67546515</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">67546520</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GGCGGC</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AR</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">nonframeshift deletion</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">chrX</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">67545317</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">67545334</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GCAGCAGCAGCAGCAGCA</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AR</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">nonframeshift deletion</td>
</tr>
<tr>
<td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">23</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">chr12</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">132677409</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">132677409</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">T</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">POLE</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">missense</td>
<td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Oligometastatic disease</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">chr13</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">32336400</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">32336401</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TC</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BRCA2</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">frameshift deletion</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">chr13</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">32338613</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">32338613</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">G</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">T</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BRCA2</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">missense</td>
</tr>
<tr>
<td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">24</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">chr11</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">108304735</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">108304735</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">G</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ATM</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">missense</td>
<td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Oligometastatic disease</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">chr13</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">32332592</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">32332592</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BRCA2</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">missense</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">chr17</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">43528665</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">43528665</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">T</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ETV4</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">missense</td>
</tr>
<tr>
<td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">25</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">chr11</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">108304735</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">108304735</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">G</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ATM</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">missense</td>
<td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Oligometastatic disease</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">chr17</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">43093454</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">43093454</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">G</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BRCA1</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">missense</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">26</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">chrX</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">67545317</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">67545346</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GCAGCAGCAGCAGCAGCAGCAGCAGCAGCA</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AR</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">nonframeshift deletion</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oligometastatic disease</td>
</tr>
<tr>
<td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">27</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">chr11</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">108254034</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">108254034</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">T</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ATM</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">missense</td>
<td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Oligometastatic disease</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">chr17</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">43533863</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">43533863</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">T</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ETV4</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">missense</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">chrX</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">67545317</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">67545322</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GCAGCA</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AR</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">nonframeshift deletion</td>
</tr>
<tr>
<td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">28</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">chr11</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">108304735</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">108304735</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">G</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ATM</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">missense</td>
<td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Oligometastatic disease</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">chr13</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">32332456</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">32332456</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BRCA2</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">missense</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">chr13</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">32332592</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">32332592</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BRCA2</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">missense</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">chrX</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">67545317</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">67545328</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GCAGCAGCAGCA</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AR</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">nonframeshift deletion</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/biomedicines-10-01321-t0A2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></section></section><section id="notes1"><h2 class="pmc_sec_title">Author Contributions</h2>
<p>Conceptualization, L.T. and S.B.; methodology, S.B. and C.F.; validation, L.T., A.C. and C.F.; formal analysis, S.B. and C.T.; investigation, L.B., A.C. and A.E.G.; resources, L.T. and R.B.; data curation, A.C. and L.B.; writing—original draft preparation, A.C. and L.B.; writing—review and editing, L.B., L.T. and C.F.; visualization, S.B.; supervision, N.P. and R.B.; project administration, D.R. and S.M.M. All authors have read and agreed to the published version of the manuscript.</p></section><section id="notes2"><h2 class="pmc_sec_title">Institutional Review Board Statement</h2>
<p>The study was conducted in accordance with the Declaration of Helsinki, and approved by the Ethics Committee of PROVINCIA DI BRESCIA—ASST SPEDALI CIVILI DI BRESCIA (protocol code NP 2813, date of approval 17 November 2017).</p></section><section id="notes3"><h2 class="pmc_sec_title">Informed Consent Statement</h2>
<p>Informed consent was obtained from all subjects involved in the study.</p></section><section id="notes4"><h2 class="pmc_sec_title">Data Availability Statement</h2>
<p>The data presented in this study are available on request from the corresponding author. The data are not publicly available due to Institutional policies, and the need for the authorization of the Study Coordinator (L.T. and S.M.M.).</p></section><section id="notes5"><h2 class="pmc_sec_title">Conflicts of Interest</h2>
<p>The authors declare no conflict of interest.</p></section><section id="funding-statement1" lang="en"><h2 class="pmc_sec_title">Funding Statement</h2>
<p>This research received no external funding.</p></section><section id="fn-group1" class="fn-group"><h2 class="pmc_sec_title">Footnotes</h2>
<div class="fn-group p font-secondary-light font-sm"><div class="fn p" id="fn3"><p><strong>Publisher’s Note:</strong> MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></div></div></section><section id="ref-list1" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="ref-list1_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="B1-biomedicines-10-01321">
<span class="label">1.</span><cite>Foster C.C., Weichselbaum R.R., Pitroda S.P. Oligometastatic Prostate Cancer: Reality or Figment of Imagination? Cancer. 2019;125:340–352. doi: 10.1002/cncr.31860.</cite> [<a href="https://doi.org/10.1002/cncr.31860" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6587458/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30521067/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer&amp;title=Oligometastatic%20Prostate%20Cancer:%20Reality%20or%20Figment%20of%20Imagination?&amp;author=C.C.%20Foster&amp;author=R.R.%20Weichselbaum&amp;author=S.P.%20Pitroda&amp;volume=125&amp;publication_year=2019&amp;pages=340-352&amp;pmid=30521067&amp;doi=10.1002/cncr.31860&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B2-biomedicines-10-01321">
<span class="label">2.</span><cite>Hellman S., Weichselbaum R.R. Oligometastases. J. Clin. Oncol. 1995;13:8–10. doi: 10.1200/JCO.1995.13.1.8.</cite> [<a href="https://doi.org/10.1200/JCO.1995.13.1.8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/7799047/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Clin.%20Oncol.&amp;title=Oligometastases&amp;author=S.%20Hellman&amp;author=R.R.%20Weichselbaum&amp;volume=13&amp;publication_year=1995&amp;pages=8-10&amp;pmid=7799047&amp;doi=10.1200/JCO.1995.13.1.8&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B3-biomedicines-10-01321">
<span class="label">3.</span><cite>Hellman S., Weichselbaum R.R. Oligometastases Revised. Nat. Rev. Clin. Oncol. 2011;8:378–382. doi: 10.1038/nrclinonc.2011.44.</cite> [<a href="https://doi.org/10.1038/nrclinonc.2011.44" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21423255/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat.%20Rev.%20Clin.%20Oncol.&amp;title=Oligometastases%20Revised&amp;author=S.%20Hellman&amp;author=R.R.%20Weichselbaum&amp;volume=8&amp;publication_year=2011&amp;pages=378-382&amp;pmid=21423255&amp;doi=10.1038/nrclinonc.2011.44&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B4-biomedicines-10-01321">
<span class="label">4.</span><cite>Reyes D.K., Pienta K.J. The biology and treatment of oligometastatic cancer. Oncotarget. 2015;6:8491–8524. doi: 10.18632/oncotarget.3455.</cite> [<a href="https://doi.org/10.18632/oncotarget.3455" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4496163/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25940699/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Oncotarget&amp;title=The%20biology%20and%20treatment%20of%20oligometastatic%20cancer&amp;author=D.K.%20Reyes&amp;author=K.J.%20Pienta&amp;volume=6&amp;publication_year=2015&amp;pages=8491-8524&amp;pmid=25940699&amp;doi=10.18632/oncotarget.3455&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B5-biomedicines-10-01321">
<span class="label">5.</span><cite>Soloway M.S., Hardeman S.W., Hickey D., Todd B., Soloway S., Raymond J., Moinuddin M. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer. 1988;61:195–202. doi: 10.1002/1097-0142(19880101)61:1&amp;#x0003c;195::AID-CNCR2820610133&amp;#x0003e;3.0.CO;2-Y.</cite> [<a href="https://doi.org/10.1002/1097-0142(19880101)61:1&amp;#x0003c;195::AID-CNCR2820610133&amp;#x0003e;3.0.CO;2-Y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/3334948/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer&amp;title=Stratification%20of%20patients%20with%20metastatic%20prostate%20cancer%20based%20on%20extent%20of%20disease%20on%20initial%20bone%20scan&amp;author=M.S.%20Soloway&amp;author=S.W.%20Hardeman&amp;author=D.%20Hickey&amp;author=B.%20Todd&amp;author=S.%20Soloway&amp;volume=61&amp;publication_year=1988&amp;pages=195-202&amp;pmid=3334948&amp;doi=10.1002/1097-0142(19880101)61:1&amp;#x0003c;195::AID-CNCR2820610133&amp;#x0003e;3.0.CO;2-Y&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B6-biomedicines-10-01321">
<span class="label">6.</span><cite>Singh D., Yi W.S., A Brasacchio R., Muhs A.G., Smudzin T., Williams J.P., Messing E., Okunieff P. Is there a favorable subset of patients with prostate cancer who develop oligometastases? Int. J. Radiat. Oncol. Biol. Phys. 2004;58:3–10. doi: 10.1016/S0360-3016(03)01442-1.</cite> [<a href="https://doi.org/10.1016/S0360-3016(03)01442-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/14697414/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int.%20J.%20Radiat.%20Oncol.%20Biol.%20Phys.&amp;title=Is%20there%20a%20favorable%20subset%20of%20patients%20with%20prostate%20cancer%20who%20develop%20oligometastases?&amp;author=D.%20Singh&amp;author=W.S.%20Yi&amp;author=R.%20A%20Brasacchio&amp;author=A.G.%20Muhs&amp;author=T.%20Smudzin&amp;volume=58&amp;publication_year=2004&amp;pages=3-10&amp;pmid=14697414&amp;doi=10.1016/S0360-3016(03)01442-1&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B7-biomedicines-10-01321">
<span class="label">7.</span><cite>Tosoian J.J., Gorin M.A., Ross A.E., Pienta K.J., Tran P.T., Schaeffer E.M. Oligometastatic prostate cancer: Definitions, clinical outcomes, and treatment considerations. Nat. Rev. Urol. 2017;14:15–25. doi: 10.1038/nrurol.2016.175.</cite> [<a href="https://doi.org/10.1038/nrurol.2016.175" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5808411/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27725639/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat.%20Rev.%20Urol.&amp;title=Oligometastatic%20prostate%20cancer:%20Definitions,%20clinical%20outcomes,%20and%20treatment%20considerations&amp;author=J.J.%20Tosoian&amp;author=M.A.%20Gorin&amp;author=A.E.%20Ross&amp;author=K.J.%20Pienta&amp;author=P.T.%20Tran&amp;volume=14&amp;publication_year=2017&amp;pages=15-25&amp;pmid=27725639&amp;doi=10.1038/nrurol.2016.175&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B8-biomedicines-10-01321">
<span class="label">8.</span><cite>Gillessen S., Omlin A., Attard G., de Bono J.S., Efstathiou E., Fizazi K., Halabi S., Nelson P.S., Sartor O., Smith M.R., et al.  Management of patients with advanced prostate cancer: Recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) Ann. Oncol. 2015;26:1589–1604. doi: 10.1093/annonc/mdv257.</cite> [<a href="https://doi.org/10.1093/annonc/mdv257" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4511225/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26041764/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ann.%20Oncol.&amp;title=Management%20of%20patients%20with%20advanced%20prostate%20cancer:%20Recommendations%20of%20the%20St%20Gallen%20Advanced%20Prostate%20Cancer%20Consensus%20Conference%20(APCCC)&amp;author=S.%20Gillessen&amp;author=A.%20Omlin&amp;author=G.%20Attard&amp;author=J.S.%20de%20Bono&amp;author=E.%20Efstathiou&amp;volume=26&amp;publication_year=2015&amp;pages=1589-1604&amp;pmid=26041764&amp;doi=10.1093/annonc/mdv257&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B9-biomedicines-10-01321">
<span class="label">9.</span><cite>Casamassima F., Masi L., Menichelli C., Bonucci I., Casamassima E., Lazzeri M., Gulisano M., Aterini S. Efficacy of eradicative radiotherapy for limited nodal metastases detected with choline PET scan in prostate cancer patients. Tumori. 2011;97:49–55. doi: 10.1177/030089161109700110.</cite> [<a href="https://doi.org/10.1177/030089161109700110" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21528664/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Tumori&amp;title=Efficacy%20of%20eradicative%20radiotherapy%20for%20limited%20nodal%20metastases%20detected%20with%20choline%20PET%20scan%20in%20prostate%20cancer%20patients&amp;author=F.%20Casamassima&amp;author=L.%20Masi&amp;author=C.%20Menichelli&amp;author=I.%20Bonucci&amp;author=E.%20Casamassima&amp;volume=97&amp;publication_year=2011&amp;pages=49-55&amp;pmid=21528664&amp;doi=10.1177/030089161109700110&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B10-biomedicines-10-01321">
<span class="label">10.</span><cite>Jereczek-Fossa B.A., Beltramo G., Fariselli L., Fodor C., Santoro L., Vavassori A., Zerini D., Gherardi F., Ascione C., Bossi-Zanetti I., et al.  Robotic image-guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastatic prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 2012;82:889–897. doi: 10.1016/j.ijrobp.2010.11.031.</cite> [<a href="https://doi.org/10.1016/j.ijrobp.2010.11.031" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21277113/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int.%20J.%20Radiat.%20Oncol.%20Biol.%20Phys.&amp;title=Robotic%20image-guided%20stereotactic%20radiotherapy,%20for%20isolated%20recurrent%20primary,%20lymph%20node%20or%20metastatic%20prostate%20cancer&amp;author=B.A.%20Jereczek-Fossa&amp;author=G.%20Beltramo&amp;author=L.%20Fariselli&amp;author=C.%20Fodor&amp;author=L.%20Santoro&amp;volume=82&amp;publication_year=2012&amp;pages=889-897&amp;pmid=21277113&amp;doi=10.1016/j.ijrobp.2010.11.031&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B11-biomedicines-10-01321">
<span class="label">11.</span><cite>Muacevic A., Kufeld M., Rist C., Wowra B., Stief C., Staehler M. Safety and feasibility of image-guided robotic radiosurgery for patients with limited bone metastases of prostate cancer. Urol. Oncol. 2013;31:455–460. doi: 10.1016/j.urolonc.2011.02.023.</cite> [<a href="https://doi.org/10.1016/j.urolonc.2011.02.023" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21481619/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Urol.%20Oncol.&amp;title=Safety%20and%20feasibility%20of%20image-guided%20robotic%20radiosurgery%20for%20patients%20with%20limited%20bone%20metastases%20of%20prostate%20cancer&amp;author=A.%20Muacevic&amp;author=M.%20Kufeld&amp;author=C.%20Rist&amp;author=B.%20Wowra&amp;author=C.%20Stief&amp;volume=31&amp;publication_year=2013&amp;pages=455-460&amp;pmid=21481619&amp;doi=10.1016/j.urolonc.2011.02.023&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B12-biomedicines-10-01321">
<span class="label">12.</span><cite>Ahmed K.A., Barney B.M., Davis B.J., Park S.S., Kwon E.D., Olivier K.R. Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer. Front. Oncol. 2013;2:215. doi: 10.3389/fonc.2012.00215.</cite> [<a href="https://doi.org/10.3389/fonc.2012.00215" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3551203/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23346551/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Front.%20Oncol.&amp;title=Stereotactic%20body%20radiation%20therapy%20in%20the%20treatment%20of%20oligometastatic%20prostate%20cancer&amp;author=K.A.%20Ahmed&amp;author=B.M.%20Barney&amp;author=B.J.%20Davis&amp;author=S.S.%20Park&amp;author=E.D.%20Kwon&amp;volume=2&amp;publication_year=2013&amp;pages=215&amp;pmid=23346551&amp;doi=10.3389/fonc.2012.00215&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B13-biomedicines-10-01321">
<span class="label">13.</span><cite>Berkovic P., De Meerleer G., Delrue L., Lambert B., Fonteyne V., Lumen N., Decaestecker K., Villeirs G., Vuye P., Ost P. Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: Deferring androgen deprivation therapy. Clin. Genitourin. Cancer. 2013;11:27–32. doi: 10.1016/j.clgc.2012.08.003.</cite> [<a href="https://doi.org/10.1016/j.clgc.2012.08.003" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23010414/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin.%20Genitourin.%20Cancer&amp;title=Salvage%20stereotactic%20body%20radiotherapy%20for%20patients%20with%20limited%20prostate%20cancer%20metastases:%20Deferring%20androgen%20deprivation%20therapy&amp;author=P.%20Berkovic&amp;author=G.%20De%20Meerleer&amp;author=L.%20Delrue&amp;author=B.%20Lambert&amp;author=V.%20Fonteyne&amp;volume=11&amp;publication_year=2013&amp;pages=27-32&amp;pmid=23010414&amp;doi=10.1016/j.clgc.2012.08.003&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B14-biomedicines-10-01321">
<span class="label">14.</span><cite>Schick U., Jorcano S., Nouet P., Rouzaud M., Vees H., Zilli T., Ratib O., Weber D.C., Miralbell R. Androgen deprivation and high-dose radiotherapy for oligometastatic prostate cancer patients with less than five regional and/or distant metastases. Acta Oncol. 2013;52:1622–1628. doi: 10.3109/0284186X.2013.764010.</cite> [<a href="https://doi.org/10.3109/0284186X.2013.764010" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23544357/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Acta%20Oncol.&amp;title=Androgen%20deprivation%20and%20high-dose%20radiotherapy%20for%20oligometastatic%20prostate%20cancer%20patients%20with%20less%20than%20five%20regional%20and/or%20distant%20metastases&amp;author=U.%20Schick&amp;author=S.%20Jorcano&amp;author=P.%20Nouet&amp;author=M.%20Rouzaud&amp;author=H.%20Vees&amp;volume=52&amp;publication_year=2013&amp;pages=1622-1628&amp;pmid=23544357&amp;doi=10.3109/0284186X.2013.764010&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B15-biomedicines-10-01321">
<span class="label">15.</span><cite>Decaestecker K., De Meerleer G., Lambert B., Delrue L., Fonteyne V., Claeys T., De Vos F., Huysse W., Hautekiet A., Maes G., et al.  Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence. Radiat. Oncol. 2014;9:135. doi: 10.1186/1748-717X-9-135.</cite> [<a href="https://doi.org/10.1186/1748-717X-9-135" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4066290/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24920079/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Radiat.%20Oncol.&amp;title=Repeated%20stereotactic%20body%20radiotherapy%20for%20oligometastatic%20prostate%20cancer%20recurrence&amp;author=K.%20Decaestecker&amp;author=G.%20De%20Meerleer&amp;author=B.%20Lambert&amp;author=L.%20Delrue&amp;author=V.%20Fonteyne&amp;volume=9&amp;publication_year=2014&amp;pages=135&amp;pmid=24920079&amp;doi=10.1186/1748-717X-9-135&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B16-biomedicines-10-01321">
<span class="label">16.</span><cite>Detti B., Bonomo P., Masi L., Doro R., Cipressi S., Iermano C., Bonucci I., Franceschini D., Di Brina L., Bakhi M., et al.  Stereotactic radiotherapy for isolated nodal recurrence of prostate cancer. World J. Urol. 2015;33:1197–1203. doi: 10.1007/s00345-014-1427-x.</cite> [<a href="https://doi.org/10.1007/s00345-014-1427-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25342516/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=World%20J.%20Urol.&amp;title=Stereotactic%20radiotherapy%20for%20isolated%20nodal%20recurrence%20of%20prostate%20cancer&amp;author=B.%20Detti&amp;author=P.%20Bonomo&amp;author=L.%20Masi&amp;author=R.%20Doro&amp;author=S.%20Cipressi&amp;volume=33&amp;publication_year=2015&amp;pages=1197-1203&amp;pmid=25342516&amp;doi=10.1007/s00345-014-1427-x&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B17-biomedicines-10-01321">
<span class="label">17.</span><cite>Ost P., Jereczek-Fossa B., Van As N., Zilli T., Muacevic A., Brown L., Casamassima F., Orecchia R., Henderson D., Olivier K., et al.  A multi-institutional analysis of stereotactic body radiotherapy for oligometastatic prostate cancer recurrence. Eur. Urol. Suppl. 2015;14:e447. doi: 10.1016/S1569-9056(15)60440-7.</cite> [<a href="https://doi.org/10.1016/S1569-9056(15)60440-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26189689/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur.%20Urol.%20Suppl.&amp;title=A%20multi-institutional%20analysis%20of%20stereotactic%20body%20radiotherapy%20for%20oligometastatic%20prostate%20cancer%20recurrence&amp;author=P.%20Ost&amp;author=B.%20Jereczek-Fossa&amp;author=N.%20Van%20As&amp;author=T.%20Zilli&amp;author=A.%20Muacevic&amp;volume=14&amp;publication_year=2015&amp;pages=e447&amp;pmid=26189689&amp;doi=10.1016/S1569-9056(15)60440-7&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B18-biomedicines-10-01321">
<span class="label">18.</span><cite>Henderson D.R., Tree A., Taylor H., Khoo V., Van As N.J. Oligometastatic prostate cancer: An evaluation of stereotactic body radiotherapy (SBRT) as an alternative to palliative androgen deprivation therapy. J. Clin. Oncol. 2015;33((Suppl. 1)):696–702. doi: 10.1200/jco.2015.33.7_suppl.229.</cite> [<a href="https://doi.org/10.1200/jco.2015.33.7_suppl.229" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Clin.%20Oncol.&amp;title=Oligometastatic%20prostate%20cancer:%20An%20evaluation%20of%20stereotactic%20body%20radiotherapy%20(SBRT)%20as%20an%20alternative%20to%20palliative%20androgen%20deprivation%20therapy&amp;author=D.R.%20Henderson&amp;author=A.%20Tree&amp;author=H.%20Taylor&amp;author=V.%20Khoo&amp;author=N.J.%20Van%20As&amp;volume=33&amp;issue=(Suppl.%201)&amp;publication_year=2015&amp;pages=696-702&amp;doi=10.1200/jco.2015.33.7_suppl.229&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B19-biomedicines-10-01321">
<span class="label">19.</span><cite>Muldermans J.L., Romak L.B., Kwon E.D., Park S.S., Olivier K.R. Stereotactic Body Radiation Therapy for Oligometastatic Prostate Cancer. Int. J. Radiat. Oncol. Biol. Phys. 2016;95:696–702. doi: 10.1016/j.ijrobp.2016.01.032.</cite> [<a href="https://doi.org/10.1016/j.ijrobp.2016.01.032" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5154616/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27131082/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int.%20J.%20Radiat.%20Oncol.%20Biol.%20Phys.&amp;title=Stereotactic%20Body%20Radiation%20Therapy%20for%20Oligometastatic%20Prostate%20Cancer&amp;author=J.L.%20Muldermans&amp;author=L.B.%20Romak&amp;author=E.D.%20Kwon&amp;author=S.S.%20Park&amp;author=K.R.%20Olivier&amp;volume=95&amp;publication_year=2016&amp;pages=696-702&amp;pmid=27131082&amp;doi=10.1016/j.ijrobp.2016.01.032&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B20-biomedicines-10-01321">
<span class="label">20.</span><cite>Ost P., Jereczek-Fossa B.A., Van As N., Zilli T., Muacevic A., Olivier K., Henderson D., Casamassima F., Orecchia R., Surgo A., et al.  Progression-free Survival Following Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Treatment-naive Recurrence: A Multi-institutional Analysis. Eur. Urol. 2016;69:9–12. doi: 10.1016/j.eururo.2015.07.004.</cite> [<a href="https://doi.org/10.1016/j.eururo.2015.07.004" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26189689/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur.%20Urol.&amp;title=Progression-free%20Survival%20Following%20Stereotactic%20Body%20Radiotherapy%20for%20Oligometastatic%20Prostate%20Cancer%20Treatment-naive%20Recurrence:%20A%20Multi-institutional%20Analysis&amp;author=P.%20Ost&amp;author=B.A.%20Jereczek-Fossa&amp;author=N.%20Van%20As&amp;author=T.%20Zilli&amp;author=A.%20Muacevic&amp;volume=69&amp;publication_year=2016&amp;pages=9-12&amp;pmid=26189689&amp;doi=10.1016/j.eururo.2015.07.004&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B21-biomedicines-10-01321">
<span class="label">21.</span><cite>Ost P., Jereczek-Fossa B.A., Van As N., Zilli T., Tree A., Henderson D., Orecchia R., Casamassima F., Surgo A., Miralbell R., et al.  Pattern of Progression after Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Nodal Recurrences. Clin. Oncol. 2016;28:e115–e120. doi: 10.1016/j.clon.2016.04.040.</cite> [<a href="https://doi.org/10.1016/j.clon.2016.04.040" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27133946/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin.%20Oncol.&amp;title=Pattern%20of%20Progression%20after%20Stereotactic%20Body%20Radiotherapy%20for%20Oligometastatic%20Prostate%20Cancer%20Nodal%20Recurrences&amp;author=P.%20Ost&amp;author=B.A.%20Jereczek-Fossa&amp;author=N.%20Van%20As&amp;author=T.%20Zilli&amp;author=A.%20Tree&amp;volume=28&amp;publication_year=2016&amp;pages=e115-e120&amp;pmid=27133946&amp;doi=10.1016/j.clon.2016.04.040&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B22-biomedicines-10-01321">
<span class="label">22.</span><cite>Tran P., Radwan N., Ross A., Reyes D., Wright J., Song D., Deville C., Deweese T., Carducci M., Schaeffer E., et al.  Stereotactic ablative radiation therapy for the treatment of oligometastatic prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 2016;96((Suppl. 1)):E248. doi: 10.1016/j.ijrobp.2016.06.1247.</cite> [<a href="https://doi.org/10.1016/j.ijrobp.2016.06.1247" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int.%20J.%20Radiat.%20Oncol.%20Biol.%20Phys.&amp;title=Stereotactic%20ablative%20radiation%20therapy%20for%20the%20treatment%20of%20oligometastatic%20prostate%20cancer&amp;author=P.%20Tran&amp;author=N.%20Radwan&amp;author=A.%20Ross&amp;author=D.%20Reyes&amp;author=J.%20Wright&amp;volume=96&amp;issue=(Suppl.%201)&amp;publication_year=2016&amp;pages=E248&amp;doi=10.1016/j.ijrobp.2016.06.1247&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B23-biomedicines-10-01321">
<span class="label">23.</span><cite>Oehler C., Zimmermann M., Curschmann J., Sumila M., Strebel R., Li Q., Schneider U., Zwahlen D. Factors predicting the benefit of stereotactic body radiation therapy for oligometastatic lymph node recurrence in prostate cancer: A single institution experience. Int. J. Radiat. Oncol. Biol. Phys. 2017;99((Suppl. 1)):E282. doi: 10.1016/j.ijrobp.2017.06.1275.</cite> [<a href="https://doi.org/10.1016/j.ijrobp.2017.06.1275" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int.%20J.%20Radiat.%20Oncol.%20Biol.%20Phys.&amp;title=Factors%20predicting%20the%20benefit%20of%20stereotactic%20body%20radiation%20therapy%20for%20oligometastatic%20lymph%20node%20recurrence%20in%20prostate%20cancer:%20A%20single%20institution%20experience&amp;author=C.%20Oehler&amp;author=M.%20Zimmermann&amp;author=J.%20Curschmann&amp;author=M.%20Sumila&amp;author=R.%20Strebel&amp;volume=99&amp;issue=(Suppl.%201)&amp;publication_year=2017&amp;pages=E282&amp;doi=10.1016/j.ijrobp.2017.06.1275&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B24-biomedicines-10-01321">
<span class="label">24.</span><cite>Jereczek-Fossa B.A., Fanetti G., Fodor C.I., Ciardo D., Santoro L., Francia C.M., Muto M., Surgo A., Zerini D., Marvaso G., et al.  Salvage Stereotactic Body Radiotherapy for Isolated Lymph Node Recurrent Prostate Cancer: Single Institution Series of 94 Consecutive Patients and 124 Lymph Nodes. Clin. Genitourin. Cancer. 2017;15:e623–e632. doi: 10.1016/j.clgc.2017.01.004.</cite> [<a href="https://doi.org/10.1016/j.clgc.2017.01.004" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28185875/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin.%20Genitourin.%20Cancer&amp;title=Salvage%20Stereotactic%20Body%20Radiotherapy%20for%20Isolated%20Lymph%20Node%20Recurrent%20Prostate%20Cancer:%20Single%20Institution%20Series%20of%2094%20Consecutive%20Patients%20and%20124%20Lymph%20Nodes&amp;author=B.A.%20Jereczek-Fossa&amp;author=G.%20Fanetti&amp;author=C.I.%20Fodor&amp;author=D.%20Ciardo&amp;author=L.%20Santoro&amp;volume=15&amp;publication_year=2017&amp;pages=e623-e632&amp;pmid=28185875&amp;doi=10.1016/j.clgc.2017.01.004&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B25-biomedicines-10-01321">
<span class="label">25.</span><cite>Ingrosso G., Trippa F., Maranzano E., Maranzano E., Carosi A., Ponti E., Arcidiacono F., Draghini L., Di Murro L., Lancia A., et al.  Stereotactic body radiotherapy in oligometastatic prostate cancer patients with isolated lymph nodes involvement: A two-institution experience. World J. Urol. 2017;35:45–49. doi: 10.1007/s00345-016-1860-0.</cite> [<a href="https://doi.org/10.1007/s00345-016-1860-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27233779/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=World%20J.%20Urol.&amp;title=Stereotactic%20body%20radiotherapy%20in%20oligometastatic%20prostate%20cancer%20patients%20with%20isolated%20lymph%20nodes%20involvement:%20A%20two-institution%20experience&amp;author=G.%20Ingrosso&amp;author=F.%20Trippa&amp;author=E.%20Maranzano&amp;author=E.%20Maranzano&amp;author=A.%20Carosi&amp;volume=35&amp;publication_year=2017&amp;pages=45-49&amp;pmid=27233779&amp;doi=10.1007/s00345-016-1860-0&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B26-biomedicines-10-01321">
<span class="label">26.</span><cite>Triggiani L., Alongi F., Buglione M., Detti B., Santoni R., Bruni A., Maranzano E., Lohr F., D’Angelillo R., Magli A., et al.  Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: New evidence from a multicentric study. Br. J. Cancer. 2017;116:1520–1525. doi: 10.1038/bjc.2017.103.</cite> [<a href="https://doi.org/10.1038/bjc.2017.103" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5518848/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28449007/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Br.%20J.%20Cancer&amp;title=Efficacy%20of%20stereotactic%20body%20radiotherapy%20in%20oligorecurrent%20and%20in%20oligoprogressive%20prostate%20cancer:%20New%20evidence%20from%20a%20multicentric%20study&amp;author=L.%20Triggiani&amp;author=F.%20Alongi&amp;author=M.%20Buglione&amp;author=B.%20Detti&amp;author=R.%20Santoni&amp;volume=116&amp;publication_year=2017&amp;pages=1520-1525&amp;pmid=28449007&amp;doi=10.1038/bjc.2017.103&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B27-biomedicines-10-01321">
<span class="label">27.</span><cite>Ponti E., Lancia A., Ost P., Trippa F., Triggiani L., Detti B., Ingrosso G. Exploring All Avenues for Radiotherapy in Oligorecurrent Prostate Cancer Disease Limited to Lymph Nodes: A Systemic Review of the Role of Stereotactic Body Radiotherapy. Eur. Urol. Focus. 2017;3:538–544. doi: 10.1016/j.euf.2017.07.006.</cite> [<a href="https://doi.org/10.1016/j.euf.2017.07.006" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28801240/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur.%20Urol.%20Focus&amp;title=Exploring%20All%20Avenues%20for%20Radiotherapy%20in%20Oligorecurrent%20Prostate%20Cancer%20Disease%20Limited%20to%20Lymph%20Nodes:%20A%20Systemic%20Review%20of%20the%20Role%20of%20Stereotactic%20Body%20Radiotherapy&amp;author=E.%20Ponti&amp;author=A.%20Lancia&amp;author=P.%20Ost&amp;author=F.%20Trippa&amp;author=L.%20Triggiani&amp;volume=3&amp;publication_year=2017&amp;pages=538-544&amp;pmid=28801240&amp;doi=10.1016/j.euf.2017.07.006&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B28-biomedicines-10-01321">
<span class="label">28.</span><cite>Triggiani L., Mazzola R., Tomasini D., Bruni A., Alicino G., Matrone F., Bortolus R., Francolini G., Detti B., Magli A., et al.  Upfront metastasis-directed therapy in oligorecurrent prostate cancer does not decrease the time from initiation of androgen deprivation therapy to castration resistance. Med. Oncol. 2021;38:72. doi: 10.1007/s12032-021-01518-6.</cite> [<a href="https://doi.org/10.1007/s12032-021-01518-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8131275/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34008151/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Med.%20Oncol.&amp;title=Upfront%20metastasis-directed%20therapy%20in%20oligorecurrent%20prostate%20cancer%20does%20not%20decrease%20the%20time%20from%20initiation%20of%20androgen%20deprivation%20therapy%20to%20castration%20resistance&amp;author=L.%20Triggiani&amp;author=R.%20Mazzola&amp;author=D.%20Tomasini&amp;author=A.%20Bruni&amp;author=G.%20Alicino&amp;volume=38&amp;publication_year=2021&amp;pages=72&amp;pmid=34008151&amp;doi=10.1007/s12032-021-01518-6&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B29-biomedicines-10-01321">
<span class="label">29.</span><cite>Mazzola R., Francolini G., Triggiani L., Napoli G., Cuccia F., Nicosia L., Livi L., Magrini S.M., Salgarello M., Alongi F. Metastasis-directed Therapy (SBRT) Guided by PET-CT 18F-CHOLINE Versus PET-CT 68Ga-PSMA in Castration-sensitive Oligorecurrent Prostate Cancer: A Comparative Analysis of Effectiveness. Clin. Genitourin. Cancer. 2021;19:230–236. doi: 10.1016/j.clgc.2020.08.002.</cite> [<a href="https://doi.org/10.1016/j.clgc.2020.08.002" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32863189/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin.%20Genitourin.%20Cancer&amp;title=Metastasis-directed%20Therapy%20(SBRT)%20Guided%20by%20PET-CT%2018F-CHOLINE%20Versus%20PET-CT%2068Ga-PSMA%20in%20Castration-sensitive%20Oligorecurrent%20Prostate%20Cancer:%20A%20Comparative%20Analysis%20of%20Effectiveness&amp;author=R.%20Mazzola&amp;author=G.%20Francolini&amp;author=L.%20Triggiani&amp;author=G.%20Napoli&amp;author=F.%20Cuccia&amp;volume=19&amp;publication_year=2021&amp;pages=230-236&amp;pmid=32863189&amp;doi=10.1016/j.clgc.2020.08.002&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B30-biomedicines-10-01321">
<span class="label">30.</span><cite>Mazzola R., Cuccia F., Pastorello E., Salgarello M., Francolini G., Livi L., Triggiani L., Magrini S.M., Ingrosso G., Aristei C., et al.  PSMA-guided metastases directed therapy for bone castration sensitive oligometastatic prostate cancer: A multi-institutional study. Clin. Exp. Metastasis. 2022;39:443–448. doi: 10.1007/s10585-022-10157-8.</cite> [<a href="https://doi.org/10.1007/s10585-022-10157-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35266063/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin.%20Exp.%20Metastasis&amp;title=PSMA-guided%20metastases%20directed%20therapy%20for%20bone%20castration%20sensitive%20oligometastatic%20prostate%20cancer:%20A%20multi-institutional%20study&amp;author=R.%20Mazzola&amp;author=F.%20Cuccia&amp;author=E.%20Pastorello&amp;author=M.%20Salgarello&amp;author=G.%20Francolini&amp;volume=39&amp;publication_year=2022&amp;pages=443-448&amp;pmid=35266063&amp;doi=10.1007/s10585-022-10157-8&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B31-biomedicines-10-01321">
<span class="label">31.</span><cite>Decaestecker K., Meerleer G.D., Ameye F., Fonteyne V., Lambert B., Joniau S., Delrue L., Billiet I., Duthoy W., Junius S., et al.  Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence (STOMP): Study protocol for a randomized Phase II Trial. BMC Cancer. 2014;14:671.  doi: 10.1186/1471-2407-14-671.</cite> [<a href="https://doi.org/10.1186/1471-2407-14-671" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4175227/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25223986/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=BMC%20Cancer&amp;title=Surveillance%20or%20Metastasis-Directed%20Therapy%20for%20Oligometastatic%20Prostate%20Cancer%20Recurrence%20(STOMP):%20Study%20protocol%20for%20a%20randomized%20Phase%20II%20Trial&amp;author=K.%20Decaestecker&amp;author=G.D.%20Meerleer&amp;author=F.%20Ameye&amp;author=V.%20Fonteyne&amp;author=B.%20Lambert&amp;volume=14&amp;publication_year=2014&amp;pages=671&amp;pmid=25223986&amp;doi=10.1186/1471-2407-14-671&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B32-biomedicines-10-01321">
<span class="label">32.</span><cite>Ost P., Reynders D., Decaestecker K., Fonteyne V., Lumen N., De Bruycker A., Lambert B., Delrue L., Bultijnck R., Claeys T., et al.  Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial. J. Clin. Oncol. 2018;36:446–453. doi: 10.1200/JCO.2017.75.4853.</cite> [<a href="https://doi.org/10.1200/JCO.2017.75.4853" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29240541/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Clin.%20Oncol.&amp;title=Surveillance%20or%20Metastasis-Directed%20Therapy%20for%20Oligometastatic%20Prostate%20Cancer%20Recurrence:%20A%20Prospective,%20Randomized,%20Multicenter%20Phase%20II%20Trial&amp;author=P.%20Ost&amp;author=D.%20Reynders&amp;author=K.%20Decaestecker&amp;author=V.%20Fonteyne&amp;author=N.%20Lumen&amp;volume=36&amp;publication_year=2018&amp;pages=446-453&amp;pmid=29240541&amp;doi=10.1200/JCO.2017.75.4853&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B33-biomedicines-10-01321">
<span class="label">33.</span><cite>Phillips R., Shi W.Y., Deek M., Radwan N., Lim S.J., Antonarakis E.S., Rowe S.P., Ros A.E., Gorin M.A., Deville C., et al.  Outcomes of Observation vs. Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial. JAMA Oncol. 2020;6:650–659. doi: 10.1001/jamaoncol.2020.0147.</cite> [<a href="https://doi.org/10.1001/jamaoncol.2020.0147" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7225913/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32215577/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JAMA%20Oncol.&amp;title=Outcomes%20of%20Observation%20vs.%20Stereotactic%20Ablative%20Radiation%20for%20Oligometastatic%20Prostate%20Cancer:%20The%20ORIOLE%20Phase%202%20Randomized%20Clinical%20Trial&amp;author=R.%20Phillips&amp;author=W.Y.%20Shi&amp;author=M.%20Deek&amp;author=N.%20Radwan&amp;author=S.J.%20Lim&amp;volume=6&amp;publication_year=2020&amp;pages=650-659&amp;pmid=32215577&amp;doi=10.1001/jamaoncol.2020.0147&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B34-biomedicines-10-01321">
<span class="label">34.</span><cite>Cornford P., van den Bergh R.C.N., Briers E., Van den Broeck T., Cumberbatch M.G., De Santis M., Fanti S., Fossati N., Gandaglia G., Gillessen S., et al.  EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. Eur. Urol. 2021;79:263–282. doi: 10.1016/j.eururo.2020.09.046.</cite> [<a href="https://doi.org/10.1016/j.eururo.2020.09.046" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33039206/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur.%20Urol.&amp;title=EAU-EANM-ESTRO-ESUR-SIOG%20Guidelines%20on%20Prostate%20Cancer.%20Part%20II-2020%20Update:%20Treatment%20of%20Relapsing%20and%20Metastatic%20Prostate%20Cancer&amp;author=P.%20Cornford&amp;author=R.C.N.%20van%20den%20Bergh&amp;author=E.%20Briers&amp;author=T.%20Van%20den%20Broeck&amp;author=M.G.%20Cumberbatch&amp;volume=79&amp;publication_year=2021&amp;pages=263-282&amp;pmid=33039206&amp;doi=10.1016/j.eururo.2020.09.046&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B35-biomedicines-10-01321">
<span class="label">35.</span><cite>The Cancer Genome Atlas Research Network  The Molecular Taxonomy of Primary Prostate Cancer. Cell. 2015;163:1011–1025. doi: 10.1016/j.cell.2015.10.025.</cite> [<a href="https://doi.org/10.1016/j.cell.2015.10.025" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4695400/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26544944/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cell&amp;title=The%20Molecular%20Taxonomy%20of%20Primary%20Prostate%20Cancer&amp;volume=163&amp;publication_year=2015&amp;pages=1011-1025&amp;pmid=26544944&amp;doi=10.1016/j.cell.2015.10.025&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B36-biomedicines-10-01321">
<span class="label">36.</span><cite>Foroni C., Zarovni N., Bianciardi L., Bernardi S., Triggiani L., Zocco D., Venturella M., Chiesi A., Valcamonico F., Berruti A. When Less Is More: Specific Capture and Analysis of Tumor Exosomes in Plasma Increases the Sensitivity of Liquid Biopsy for Comprehensive Detection of Multiple Androgen Receptor Phenotypes in Advanced Prostate Cancer Patients. Biomedicine. 2020;8:131.  doi: 10.3390/biomedicines8050131.</cite> [<a href="https://doi.org/10.3390/biomedicines8050131" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7277361/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32455948/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Biomedicine&amp;title=When%20Less%20Is%20More:%20Specific%20Capture%20and%20Analysis%20of%20Tumor%20Exosomes%20in%20Plasma%20Increases%20the%20Sensitivity%20of%20Liquid%20Biopsy%20for%20Comprehensive%20Detection%20of%20Multiple%20Androgen%20Receptor%20Phenotypes%20in%20Advanced%20Prostate%20Cancer%20Patients&amp;author=C.%20Foroni&amp;author=N.%20Zarovni&amp;author=L.%20Bianciardi&amp;author=S.%20Bernardi&amp;author=L.%20Triggiani&amp;volume=8&amp;publication_year=2020&amp;pages=131&amp;pmid=32455948&amp;doi=10.3390/biomedicines8050131&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B37-biomedicines-10-01321">
<span class="label">37.</span><cite>Bardelli A., Pantel K. Liquid Biopsies, What We Do Not Know (Yet) Cancer Cell. 2017;31:172–179. doi: 10.1016/j.ccell.2017.01.002.</cite> [<a href="https://doi.org/10.1016/j.ccell.2017.01.002" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28196593/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Cell&amp;title=Liquid%20Biopsies,%20What%20We%20Do%20Not%20Know%20(Yet)&amp;author=A.%20Bardelli&amp;author=K.%20Pantel&amp;volume=31&amp;publication_year=2017&amp;pages=172-179&amp;pmid=28196593&amp;doi=10.1016/j.ccell.2017.01.002&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B38-biomedicines-10-01321">
<span class="label">38.</span><cite>Shyr D., Liu Q. Next generation sequencing in cancer research and clinical application. Biol. Proced. Online. 2013;15:4. doi: 10.1186/1480-9222-15-4.</cite> [<a href="https://doi.org/10.1186/1480-9222-15-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3599179/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23406336/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Biol.%20Proced.%20Online&amp;title=Next%20generation%20sequencing%20in%20cancer%20research%20and%20clinical%20application&amp;author=D.%20Shyr&amp;author=Q.%20Liu&amp;volume=15&amp;publication_year=2013&amp;pages=4&amp;pmid=23406336&amp;doi=10.1186/1480-9222-15-4&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B39-biomedicines-10-01321">
<span class="label">39.</span><cite>Beltran H., Yelensky R., Frampton G.M., Park K., Downing S.R., MacDonald T.Y., Jarosz M., Lipson D., Tagawa S.T., Nanus D.M., et al.  Targeted Next-generation Sequencing of Advanced Prostate Cancer Identifies Potential Therapeutic Targets and Disease Heterogeneity. Eur. Urol. 2013;63:920–926. doi: 10.1016/j.eururo.2012.08.053.</cite> [<a href="https://doi.org/10.1016/j.eururo.2012.08.053" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3615043/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22981675/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur.%20Urol.&amp;title=Targeted%20Next-generation%20Sequencing%20of%20Advanced%20Prostate%20Cancer%20Identifies%20Potential%20Therapeutic%20Targets%20and%20Disease%20Heterogeneity&amp;author=H.%20Beltran&amp;author=R.%20Yelensky&amp;author=G.M.%20Frampton&amp;author=K.%20Park&amp;author=S.R.%20Downing&amp;volume=63&amp;publication_year=2013&amp;pages=920-926&amp;pmid=22981675&amp;doi=10.1016/j.eururo.2012.08.053&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B40-biomedicines-10-01321">
<span class="label">40.</span><cite>Triggiani L., Bardoscia L., Colosini A., Bernardi S., Bresciani R., Foroni C., Pasinetti N., Borghetti P., Caraffini B., Orizio F., et al.  Oligometastatic prostate cancer patients stratification: A molecular signature identified by liquid biopsy. J. Clin. Oncol. 2018;36((Suppl. 6)):TPS400. doi: 10.1200/JCO.2018.36.6_suppl.TPS400.</cite> [<a href="https://doi.org/10.1200/JCO.2018.36.6_suppl.TPS400" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Clin.%20Oncol.&amp;title=Oligometastatic%20prostate%20cancer%20patients%20stratification:%20A%20molecular%20signature%20identified%20by%20liquid%20biopsy&amp;author=L.%20Triggiani&amp;author=L.%20Bardoscia&amp;author=A.%20Colosini&amp;author=S.%20Bernardi&amp;author=R.%20Bresciani&amp;volume=36&amp;issue=(Suppl.%206)&amp;publication_year=2018&amp;pages=TPS400&amp;doi=10.1200/JCO.2018.36.6_suppl.TPS400&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B41-biomedicines-10-01321">
<span class="label">41.</span><cite>World Medical Association  Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. JAMA. 2013;310:2191–2194. doi: 10.1001/jama.2013.281053.</cite> [<a href="https://doi.org/10.1001/jama.2013.281053" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24141714/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JAMA&amp;title=Declaration%20of%20Helsinki:%20Ethical%20Principles%20for%20Medical%20Research%20Involving%20Human%20Subjects&amp;volume=310&amp;publication_year=2013&amp;pages=2191-2194&amp;pmid=24141714&amp;doi=10.1001/jama.2013.281053&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B42-biomedicines-10-01321">
<span class="label">42.</span><cite>Cornford P., Bellmunt J., Bolla M., Briers E., De Santis M., Gross T., Henry A.M., Joniau S., Lam T.B., Mason M.D., et al.  EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. Eur. Urol. 2017;71:630–642. doi: 10.1016/j.eururo.2016.08.002.</cite> [<a href="https://doi.org/10.1016/j.eururo.2016.08.002" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27591931/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur.%20Urol.&amp;title=EAU-ESTRO-SIOG%20Guidelines%20on%20Prostate%20Cancer.%20Part%20II:%20Treatment%20of%20Relapsing,%20Metastatic,%20and%20Castration-Resistant%20Prostate%20Cancer&amp;author=P.%20Cornford&amp;author=J.%20Bellmunt&amp;author=M.%20Bolla&amp;author=E.%20Briers&amp;author=M.%20De%20Santis&amp;volume=71&amp;publication_year=2017&amp;pages=630-642&amp;pmid=27591931&amp;doi=10.1016/j.eururo.2016.08.002&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B43-biomedicines-10-01321">
<span class="label">43.</span><cite>Van Etten J.L., Dehm S.M. Clonal origin and spread of metastatic prostate cancer. Endocr. Relat. Cancer. 2016;23:R207–R217. doi: 10.1530/ERC-16-0049.</cite> [<a href="https://doi.org/10.1530/ERC-16-0049" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4895916/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27000662/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Endocr.%20Relat.%20Cancer&amp;title=Clonal%20origin%20and%20spread%20of%20metastatic%20prostate%20cancer&amp;author=J.L.%20Van%20Etten&amp;author=S.M.%20Dehm&amp;volume=23&amp;publication_year=2016&amp;pages=R207-R217&amp;pmid=27000662&amp;doi=10.1530/ERC-16-0049&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B44-biomedicines-10-01321">
<span class="label">44.</span><cite>Bernardi S., Farina M., Zanaglio C., Cattina F., Polverelli N., Schieppati F., Re F., Foroni C., Malagola M., Dunbar A.J., et al.  ETV6: A Candidate Gene for Predisposition to “Blend Pedigrees”? A Case Report from the NEXT-Famly Clinical Trial. Case Rep Hematol. 2020;2020:2795656. doi: 10.1155/2020/2795656.</cite> [<a href="https://doi.org/10.1155/2020/2795656" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7057007/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32148977/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Case%20Rep%20Hematol.&amp;title=ETV6:%20A%20Candidate%20Gene%20for%20Predisposition%20to%20%E2%80%9CBlend%20Pedigrees%E2%80%9D?%20A%20Case%20Report%20from%20the%20NEXT-Famly%20Clinical%20Trial&amp;author=S.%20Bernardi&amp;author=M.%20Farina&amp;author=C.%20Zanaglio&amp;author=F.%20Cattina&amp;author=N.%20Polverelli&amp;volume=2020&amp;publication_year=2020&amp;pages=2795656&amp;pmid=32148977&amp;doi=10.1155/2020/2795656&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B45-biomedicines-10-01321">
<span class="label">45.</span><cite>Arora K., Barbieri C.E. Molecular Subtypes of Prostate Cancer. Curr. Oncol. Rep. 2018;20:58. doi: 10.1007/s11912-018-0707-9.</cite> [<a href="https://doi.org/10.1007/s11912-018-0707-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29858674/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Curr.%20Oncol.%20Rep.&amp;title=Molecular%20Subtypes%20of%20Prostate%20Cancer&amp;author=K.%20Arora&amp;author=C.E.%20Barbieri&amp;volume=20&amp;publication_year=2018&amp;pages=58&amp;pmid=29858674&amp;doi=10.1007/s11912-018-0707-9&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B46-biomedicines-10-01321">
<span class="label">46.</span><cite>Robinson D., Van Allen E.M., Wu Y.M., Schultz N., Lonigro R.J., Mosquera J.M., Montgomery B., Taplin M.E., Pritchard C.C., Attard G., et al.  Integrative Clinical Genomics of Advanced Prostate Cancer. Cell. 2015;161:1215–1228. doi: 10.1016/j.cell.2015.05.001.</cite> [<a href="https://doi.org/10.1016/j.cell.2015.05.001" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4484602/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26000489/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cell&amp;title=Integrative%20Clinical%20Genomics%20of%20Advanced%20Prostate%20Cancer&amp;author=D.%20Robinson&amp;author=E.M.%20Van%20Allen&amp;author=Y.M.%20Wu&amp;author=N.%20Schultz&amp;author=R.J.%20Lonigro&amp;volume=161&amp;publication_year=2015&amp;pages=1215-1228&amp;pmid=26000489&amp;doi=10.1016/j.cell.2015.05.001&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B47-biomedicines-10-01321">
<span class="label">47.</span><cite>Sumanasuriya S., De Bono J. Treatment of Advanced Prostate Cancer—A Review of Current Therapies and Future Promise. Cold Spring Harb. Perspect. Med. 2018;8:a030635. doi: 10.1101/cshperspect.a030635.</cite> [<a href="https://doi.org/10.1101/cshperspect.a030635" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5983161/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29101113/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cold%20Spring%20Harb.%20Perspect.%20Med.&amp;title=Treatment%20of%20Advanced%20Prostate%20Cancer%E2%80%94A%20Review%20of%20Current%20Therapies%20and%20Future%20Promise&amp;author=S.%20Sumanasuriya&amp;author=J.%20De%20Bono&amp;volume=8&amp;publication_year=2018&amp;pages=a030635&amp;pmid=29101113&amp;doi=10.1101/cshperspect.a030635&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B48-biomedicines-10-01321">
<span class="label">48.</span><cite>Alix-Panabières C., Pantel K. Liquid Biopsy: From Discovery to Clinical Application. Cancer Discov. 2021;11:858–873. doi: 10.1158/2159-8290.CD-20-1311.</cite> [<a href="https://doi.org/10.1158/2159-8290.CD-20-1311" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33811121/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Discov.&amp;title=Liquid%20Biopsy:%20From%20Discovery%20to%20Clinical%20Application&amp;author=C.%20Alix-Panabi%C3%A8res&amp;author=K.%20Pantel&amp;volume=11&amp;publication_year=2021&amp;pages=858-873&amp;pmid=33811121&amp;doi=10.1158/2159-8290.CD-20-1311&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B49-biomedicines-10-01321">
<span class="label">49.</span><cite>Clarke N., Wienchno P., Alekseev B., Sala N., Jones R., Kocak I., Chiuri V.E., Jassem J., Flechon A., Redfern C., et al.  Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: A randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2018;19:975–986. doi: 10.1016/S1470-2045(18)30365-6.</cite> [<a href="https://doi.org/10.1016/S1470-2045(18)30365-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29880291/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet%20Oncol.&amp;title=Olaparib%20combined%20with%20abiraterone%20in%20patients%20with%20metastatic%20castration-resistant%20prostate%20cancer:%20A%20randomised,%20double-blind,%20placebo-controlled,%20phase%202%20trial&amp;author=N.%20Clarke&amp;author=P.%20Wienchno&amp;author=B.%20Alekseev&amp;author=N.%20Sala&amp;author=R.%20Jones&amp;volume=19&amp;publication_year=2018&amp;pages=975-986&amp;pmid=29880291&amp;doi=10.1016/S1470-2045(18)30365-6&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B50-biomedicines-10-01321">
<span class="label">50.</span><cite>Carr T.H., Adelman C., Barnicle A., Kozarewa I., Luke S., Lai Z., Hollis S., Dougherty B., Harrington E.A., Kang J., et al.  Homologous Recombination Repair Gene Mutation Characterization by Liquid Biopsy: A Phase II Trial of Olaparib and Abiraterone in Metastatic Castrate-Resistant Prostate Cancer. Cancers. 2021;13:5830.  doi: 10.3390/cancers13225830.</cite> [<a href="https://doi.org/10.3390/cancers13225830" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8616430/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34830984/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancers&amp;title=Homologous%20Recombination%20Repair%20Gene%20Mutation%20Characterization%20by%20Liquid%20Biopsy:%20A%20Phase%20II%20Trial%20of%20Olaparib%20and%20Abiraterone%20in%20Metastatic%20Castrate-Resistant%20Prostate%20Cancer&amp;author=T.H.%20Carr&amp;author=C.%20Adelman&amp;author=A.%20Barnicle&amp;author=I.%20Kozarewa&amp;author=S.%20Luke&amp;volume=13&amp;publication_year=2021&amp;pages=5830&amp;pmid=34830984&amp;doi=10.3390/cancers13225830&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B51-biomedicines-10-01321">
<span class="label">51.</span><cite>Zocco D., Bernardi S., Novelli M., Astrua C., Fava P., Zarovni N., Carpi F.M., Bianciardi L., Malavenda O., Quaglino P., et al.  Isolation of extracellular vesicles improves the detection of mutant DNA from plasma of metastatic melanoma patients. Sci. Rep. 2020;10:15745. doi: 10.1038/s41598-020-72834-6.</cite> [<a href="https://doi.org/10.1038/s41598-020-72834-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7519075/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32978468/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Sci.%20Rep.&amp;title=Isolation%20of%20extracellular%20vesicles%20improves%20the%20detection%20of%20mutant%20DNA%20from%20plasma%20of%20metastatic%20melanoma%20patients&amp;author=D.%20Zocco&amp;author=S.%20Bernardi&amp;author=M.%20Novelli&amp;author=C.%20Astrua&amp;author=P.%20Fava&amp;volume=10&amp;publication_year=2020&amp;pages=15745&amp;pmid=32978468&amp;doi=10.1038/s41598-020-72834-6&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B52-biomedicines-10-01321">
<span class="label">52.</span><cite>Nicholls L., Chapman E., Khoo V., Suh Y.E., Tunariu N., Wang Y., van As N. Metastasis-directed Therapy in Prostate Cancer: Prognostic Significance of the ESTRO/EORTC Classification in Oligometastatic Bone Disease. Clin. Oncol. 2022;34:63–69. doi: 10.1016/j.clon.2021.10.004.</cite> [<a href="https://doi.org/10.1016/j.clon.2021.10.004" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34756755/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin.%20Oncol.&amp;title=Metastasis-directed%20Therapy%20in%20Prostate%20Cancer:%20Prognostic%20Significance%20of%20the%20ESTRO/EORTC%20Classification%20in%20Oligometastatic%20Bone%20Disease&amp;author=L.%20Nicholls&amp;author=E.%20Chapman&amp;author=V.%20Khoo&amp;author=Y.E.%20Suh&amp;author=N.%20Tunariu&amp;volume=34&amp;publication_year=2022&amp;pages=63-69&amp;pmid=34756755&amp;doi=10.1016/j.clon.2021.10.004&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B53-biomedicines-10-01321">
<span class="label">53.</span><cite>Stelcer E., Konkol M., Głeboka A., Suchorska W.M. Liquid Biopsy in Oligometastatic Prostate Cancer—A Biologist’s Point of View. Front. Oncol. 2019;9:775. doi: 10.3389/fonc.2019.00775.</cite> [<a href="https://doi.org/10.3389/fonc.2019.00775" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6702517/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31475117/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Front.%20Oncol.&amp;title=Liquid%20Biopsy%20in%20Oligometastatic%20Prostate%20Cancer%E2%80%94A%20Biologist%E2%80%99s%20Point%20of%20View&amp;author=E.%20Stelcer&amp;author=M.%20Konkol&amp;author=A.%20G%C5%82eboka&amp;author=W.M.%20Suchorska&amp;volume=9&amp;publication_year=2019&amp;pages=775&amp;pmid=31475117&amp;doi=10.3389/fonc.2019.00775&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B54-biomedicines-10-01321">
<span class="label">54.</span><cite>Gorges T.M., Kuske A., Rock K., Mauermann O., Muller V., Peine S., Verpoort K., Novosadova V., Kubista M., Riethdorf S., et al.  Accession of tumor heterogeneity by multiplex transcriptome profiling of single circulating tumor cells. Clin. Chem. 2016;62:1504–1515. doi: 10.1373/clinchem.2016.260299.</cite> [<a href="https://doi.org/10.1373/clinchem.2016.260299" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27630154/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin.%20Chem&amp;title=Accession%20of%20tumor%20heterogeneity%20by%20multiplex%20transcriptome%20profiling%20of%20single%20circulating%20tumor%20cells&amp;author=T.M.%20Gorges&amp;author=A.%20Kuske&amp;author=K.%20Rock&amp;author=O.%20Mauermann&amp;author=V.%20Muller&amp;volume=62&amp;publication_year=2016&amp;pages=1504-1515&amp;pmid=27630154&amp;doi=10.1373/clinchem.2016.260299&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B55-biomedicines-10-01321">
<span class="label">55.</span><cite>Scher H.I., Graf R.P., Schreiber N.A., McLaughlin B., Jendrisak A., Wang Y., Lee J., Greene S., Krupa R., Lu D., et al.  Phenotypic heterogeneity of circulating tumor cells informs clinical decisions between AR signaling inhibitors and taxanes in metastatic prostate cancer. Cancer Res. 2017;77:5687–5698. doi: 10.1158/0008-5472.CAN-17-1353.</cite> [<a href="https://doi.org/10.1158/0008-5472.CAN-17-1353" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5666339/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28819021/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Res.&amp;title=Phenotypic%20heterogeneity%20of%20circulating%20tumor%20cells%20informs%20clinical%20decisions%20between%20AR%20signaling%20inhibitors%20and%20taxanes%20in%20metastatic%20prostate%20cancer&amp;author=H.I.%20Scher&amp;author=R.P.%20Graf&amp;author=N.A.%20Schreiber&amp;author=B.%20McLaughlin&amp;author=A.%20Jendrisak&amp;volume=77&amp;publication_year=2017&amp;pages=5687-5698&amp;pmid=28819021&amp;doi=10.1158/0008-5472.CAN-17-1353&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B56-biomedicines-10-01321">
<span class="label">56.</span><cite>Pereira B., Chen C.T., Goyal L., Walmsley C., Pinto C.J., Baiev I., Allen R., Henderson L., Saha S., Reyes S., et al.  Cell-free DNA captures tumor heterogeneity and driver alterations in rapid autopsies with pre-treated metastatic cancer. Nat. Commun. 2021;12:3199. doi: 10.1038/s41467-021-23394-4.</cite> [<a href="https://doi.org/10.1038/s41467-021-23394-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8160338/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34045463/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat.%20Commun.&amp;title=Cell-free%20DNA%20captures%20tumor%20heterogeneity%20and%20driver%20alterations%20in%20rapid%20autopsies%20with%20pre-treated%20metastatic%20cancer&amp;author=B.%20Pereira&amp;author=C.T.%20Chen&amp;author=L.%20Goyal&amp;author=C.%20Walmsley&amp;author=C.J.%20Pinto&amp;volume=12&amp;publication_year=2021&amp;pages=3199&amp;pmid=34045463&amp;doi=10.1038/s41467-021-23394-4&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B57-biomedicines-10-01321">
<span class="label">57.</span><cite>Tsui D.W.Y., Cheng M.L., Shady M., Yang J.L., Stephens D., Won H., Srinivasan P., Huberman K., Meng F., Jing X., et al.  Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients. Genome Med. 2021;13:96. doi: 10.1186/s13073-021-00898-8.</cite> [<a href="https://doi.org/10.1186/s13073-021-00898-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8165771/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34059130/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Genome%20Med.&amp;title=Tumor%20fraction-guided%20cell-free%20DNA%20profiling%20in%20metastatic%20solid%20tumor%20patients&amp;author=D.W.Y.%20Tsui&amp;author=M.L.%20Cheng&amp;author=M.%20Shady&amp;author=J.L.%20Yang&amp;author=D.%20Stephens&amp;volume=13&amp;publication_year=2021&amp;pages=96&amp;pmid=34059130&amp;doi=10.1186/s13073-021-00898-8&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B58-biomedicines-10-01321">
<span class="label">58.</span><cite>Perkins G., Yap T.A., Pope L., Cassidy A.M., Dukes J.P., Riisnaes R., Massard C., Cassier P.A., Miranda S., Clark J., et al.  Multi-Purpose Utility of Circulating Plasma DNA Testing in Patients with Advanced Cancers. PLoS ONE. 2012;7:e47020.  doi: 10.1371/journal.pone.0047020.</cite> [<a href="https://doi.org/10.1371/journal.pone.0047020" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3492590/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23144797/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=PLoS%20ONE&amp;title=Multi-Purpose%20Utility%20of%20Circulating%20Plasma%20DNA%20Testing%20in%20Patients%20with%20Advanced%20Cancers&amp;author=G.%20Perkins&amp;author=T.A.%20Yap&amp;author=L.%20Pope&amp;author=A.M.%20Cassidy&amp;author=J.P.%20Dukes&amp;volume=7&amp;publication_year=2012&amp;pages=e47020&amp;pmid=23144797&amp;doi=10.1371/journal.pone.0047020&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B59-biomedicines-10-01321">
<span class="label">59.</span><cite>Tan M.H.E., Jun L.I., Xu H.E., Melcher K., Yong E.L. Androgen receptor: Structure, role in prostate cancer and drug discovery. Acta Pharmacol. Sin. 2015;36:3–23. doi: 10.1038/aps.2014.18.</cite> [<a href="https://doi.org/10.1038/aps.2014.18" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4571323/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24909511/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Acta%20Pharmacol.%20Sin.&amp;title=Androgen%20receptor:%20Structure,%20role%20in%20prostate%20cancer%20and%20drug%20discovery&amp;author=M.H.E.%20Tan&amp;author=L.I.%20Jun&amp;author=H.E.%20Xu&amp;author=K.%20Melcher&amp;author=E.L.%20Yong&amp;volume=36&amp;publication_year=2015&amp;pages=3-23&amp;pmid=24909511&amp;doi=10.1038/aps.2014.18&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B60-biomedicines-10-01321">
<span class="label">60.</span><cite>Oh M., Alkhushaym N., Fallatah S., Althagafi A., Aljadeed R., Alsowaida Y., Jeter J., Martin J.R., Babiker H.M., McBride A., et al.  The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: A meta-analysis. Prostate. 2019;79:880–895. doi: 10.1002/pros.23795.</cite> [<a href="https://doi.org/10.1002/pros.23795" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30900310/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Prostate&amp;title=The%20association%20of%20BRCA1%20and%20BRCA2%20mutations%20with%20prostate%20cancer%20risk,%20frequency,%20and%20mortality:%20A%20meta-analysis&amp;author=M.%20Oh&amp;author=N.%20Alkhushaym&amp;author=S.%20Fallatah&amp;author=A.%20Althagafi&amp;author=R.%20Aljadeed&amp;volume=79&amp;publication_year=2019&amp;pages=880-895&amp;pmid=30900310&amp;doi=10.1002/pros.23795&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B61-biomedicines-10-01321">
<span class="label">61.</span><cite>Annala M., Vandekerkhove G., Khalaf D., Taavitsainen S., Beja K., Warner E.W., Sunderland K., Kollmannsberger C., Eigl B.J., Finch D., et al.  Criculating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer. Cancer Discov. 2018;8:444–457. doi: 10.1158/2159-8290.CD-17-0937.</cite> [<a href="https://doi.org/10.1158/2159-8290.CD-17-0937" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29367197/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Discov.&amp;title=Criculating%20Tumor%20DNA%20Genomics%20Correlate%20with%20Resistance%20to%20Abiraterone%20and%20Enzalutamide%20in%20Prostate%20Cancer&amp;author=M.%20Annala&amp;author=G.%20Vandekerkhove&amp;author=D.%20Khalaf&amp;author=S.%20Taavitsainen&amp;author=K.%20Beja&amp;volume=8&amp;publication_year=2018&amp;pages=444-457&amp;pmid=29367197&amp;doi=10.1158/2159-8290.CD-17-0937&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B62-biomedicines-10-01321">
<span class="label">62.</span><cite>Carter H.B., Helfand B., Mamawala M., Wu Y., Landis P., HYu H., Wiley K., Na R., Shi Z., Petkewicz J., et al.  Germline Mutations in ATM and BRCA1/2 Are Associated with Grade Reclassification in Men on Active Surveillance for Prosate Cancer. Eur. Urol. 2019;75:743–749. doi: 10.1016/j.eururo.2018.09.021.</cite> [<a href="https://doi.org/10.1016/j.eururo.2018.09.021" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6699614/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30309687/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur.%20Urol.&amp;title=Germline%20Mutations%20in%20ATM%20and%20BRCA1/2%20Are%20Associated%20with%20Grade%20Reclassification%20in%20Men%20on%20Active%20Surveillance%20for%20Prosate%20Cancer&amp;author=H.B.%20Carter&amp;author=B.%20Helfand&amp;author=M.%20Mamawala&amp;author=Y.%20Wu&amp;author=P.%20Landis&amp;volume=75&amp;publication_year=2019&amp;pages=743-749&amp;pmid=30309687&amp;doi=10.1016/j.eururo.2018.09.021&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B63-biomedicines-10-01321">
<span class="label">63.</span><cite>Meyer A., Wilhelm B., Dork T., Bremer M., Baumann R., Karstens H.J., Machtens S. ATM missense variant P1054R predispose to prostate cancer. Radiother. Oncol. 2007;83:283–288. doi: 10.1016/j.radonc.2007.04.029.</cite> [<a href="https://doi.org/10.1016/j.radonc.2007.04.029" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17502119/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Radiother.%20Oncol.&amp;title=ATM%20missense%20variant%20P1054R%20predispose%20to%20prostate%20cancer&amp;author=A.%20Meyer&amp;author=B.%20Wilhelm&amp;author=T.%20Dork&amp;author=M.%20Bremer&amp;author=R.%20Baumann&amp;volume=83&amp;publication_year=2007&amp;pages=283-288&amp;pmid=17502119&amp;doi=10.1016/j.radonc.2007.04.029&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B64-biomedicines-10-01321">
<span class="label">64.</span><cite>Pitroda S.P., Weichselbaum R.R. Integrated molecular and clinical staging defines the spectrum of metastatic cancer. Nat Rev Clin. Oncol. 2019;16:581–588. doi: 10.1038/s41571-019-0220-6.</cite> [<a href="https://doi.org/10.1038/s41571-019-0220-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31092903/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat%20Rev%20Clin.%20Oncol.&amp;title=Integrated%20molecular%20and%20clinical%20staging%20defines%20the%20spectrum%20of%20metastatic%20cancer&amp;author=S.P.%20Pitroda&amp;author=R.R.%20Weichselbaum&amp;volume=16&amp;publication_year=2019&amp;pages=581-588&amp;pmid=31092903&amp;doi=10.1038/s41571-019-0220-6&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B65-biomedicines-10-01321">
<span class="label">65.</span><cite>Bignardi M., Cozzi L., Fogliata A., Lattuada P., Mancosu P., Navarria P., Urso G., Vigorito S., Scorsetti M. Critical appraisal of volumetric modulated arc therapy in stereotactic body radiation therapy for metastases to abdominal lymph nodes. Int. J. Radiat. Oncol. Biol. Phys. 2009;75:1570–1577. doi: 10.1016/j.ijrobp.2009.05.035.</cite> [<a href="https://doi.org/10.1016/j.ijrobp.2009.05.035" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19880261/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int.%20J.%20Radiat.%20Oncol.%20Biol.%20Phys.&amp;title=Critical%20appraisal%20of%20volumetric%20modulated%20arc%20therapy%20in%20stereotactic%20body%20radiation%20therapy%20for%20metastases%20to%20abdominal%20lymph%20nodes&amp;author=M.%20Bignardi&amp;author=L.%20Cozzi&amp;author=A.%20Fogliata&amp;author=P.%20Lattuada&amp;author=P.%20Mancosu&amp;volume=75&amp;publication_year=2009&amp;pages=1570-1577&amp;pmid=19880261&amp;doi=10.1016/j.ijrobp.2009.05.035&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B66-biomedicines-10-01321">
<span class="label">66.</span><cite>Jereczek-Fossa B.A., Fariselli L., Beltramo G., Catalano G., Serafini F., Garibaldi C., Cambria R., Brait L., Possanzini M., Bianchi L.C., et al.  Linac-based or robotic image-guided stereotactic radiotherapy for isolated lymph node recurrent prostate cancer. Radiother. Oncol. 2009;93:14–17. doi: 10.1016/j.radonc.2009.04.001.</cite> [<a href="https://doi.org/10.1016/j.radonc.2009.04.001" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19409636/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Radiother.%20Oncol.&amp;title=Linac-based%20or%20robotic%20image-guided%20stereotactic%20radiotherapy%20for%20isolated%20lymph%20node%20recurrent%20prostate%20cancer&amp;author=B.A.%20Jereczek-Fossa&amp;author=L.%20Fariselli&amp;author=G.%20Beltramo&amp;author=G.%20Catalano&amp;author=F.%20Serafini&amp;volume=93&amp;publication_year=2009&amp;pages=14-17&amp;pmid=19409636&amp;doi=10.1016/j.radonc.2009.04.001&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B67-biomedicines-10-01321">
<span class="label">67.</span><cite>Benedict S.H., Yenice K.M., Followill D., Galvin J.M., Hinson W., Kavanagh B., Keall P., Lovelock M., Meeks S., Papiez L., et al.  Stereotactic body radiation therapy: The report of AAPM Task Group 101. Med. Phys. 2010;37:4078–4101. doi: 10.1118/1.3438081.</cite> [<a href="https://doi.org/10.1118/1.3438081" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20879569/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Med.%20Phys.&amp;title=Stereotactic%20body%20radiation%20therapy:%20The%20report%20of%20AAPM%20Task%20Group%20101&amp;author=S.H.%20Benedict&amp;author=K.M.%20Yenice&amp;author=D.%20Followill&amp;author=J.M.%20Galvin&amp;author=W.%20Hinson&amp;volume=37&amp;publication_year=2010&amp;pages=4078-4101&amp;pmid=20879569&amp;doi=10.1118/1.3438081&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B68-biomedicines-10-01321">
<span class="label">68.</span><cite>Bignardi M., Navarria P., Mancosu P., Cozzi L., Fogliata A., Tozzi A., Castiglioni S., Carnaghi C., Tronconi M.C., Santoro A., et al.  Clinical outcome of hypofractionated stereotactic radiotherapy for abdominal lymph node metastases. Int. J. Radiat. Oncol. Biol. Phys. 2011;81:831–838. doi: 10.1016/j.ijrobp.2010.05.032.</cite> [<a href="https://doi.org/10.1016/j.ijrobp.2010.05.032" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20800375/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int.%20J.%20Radiat.%20Oncol.%20Biol.%20Phys.&amp;title=Clinical%20outcome%20of%20hypofractionated%20stereotactic%20radiotherapy%20for%20abdominal%20lymph%20node%20metastases&amp;author=M.%20Bignardi&amp;author=P.%20Navarria&amp;author=P.%20Mancosu&amp;author=L.%20Cozzi&amp;author=A.%20Fogliata&amp;volume=81&amp;publication_year=2011&amp;pages=831-838&amp;pmid=20800375&amp;doi=10.1016/j.ijrobp.2010.05.032&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B69-biomedicines-10-01321">
<span class="label">69.</span><cite>Alongi F., Fogliata A., Clerici E., Navarria P., Tozzi A., Comito T., Ascolese A.M., Clivio A., Lobefalo F., Reggiori G., et al.  Volumetric modulated arc therapy with flattening filter free beams for isolated abdominal/pelvic lymph nodes: Report of dosimetric and early clinical results in oligometastatic patients. Radiat. Oncol. 2012;7:204. doi: 10.1186/1748-717X-7-204.</cite> [<a href="https://doi.org/10.1186/1748-717X-7-204" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3551769/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23216821/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Radiat.%20Oncol.&amp;title=Volumetric%20modulated%20arc%20therapy%20with%20flattening%20filter%20free%20beams%20for%20isolated%20abdominal/pelvic%20lymph%20nodes:%20Report%20of%20dosimetric%20and%20early%20clinical%20results%20in%20oligometastatic%20patients&amp;author=F.%20Alongi&amp;author=A.%20Fogliata&amp;author=E.%20Clerici&amp;author=P.%20Navarria&amp;author=A.%20Tozzi&amp;volume=7&amp;publication_year=2012&amp;pages=204&amp;pmid=23216821&amp;doi=10.1186/1748-717X-7-204&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B70-biomedicines-10-01321">
<span class="label">70.</span><cite>Jereczek-Fossa B.A., Piperno G., Ronchi S., Catalano G., Fodor C., Cambria R., Ing P.F., Gherardi F., Alterio D., Zerini D., et al.  Linac-based stereotactic body radiotherapy for oligometastatic patients with single abdominal lymph node recurrent cancer. Am. J. Clin. Oncol. 2014;37:227–233. doi: 10.1097/COC.0b013e3182610878.</cite> [<a href="https://doi.org/10.1097/COC.0b013e3182610878" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22992626/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Am.%20J.%20Clin.%20Oncol.&amp;title=Linac-based%20stereotactic%20body%20radiotherapy%20for%20oligometastatic%20patients%20with%20single%20abdominal%20lymph%20node%20recurrent%20cancer&amp;author=B.A.%20Jereczek-Fossa&amp;author=G.%20Piperno&amp;author=S.%20Ronchi&amp;author=G.%20Catalano&amp;author=C.%20Fodor&amp;volume=37&amp;publication_year=2014&amp;pages=227-233&amp;pmid=22992626&amp;doi=10.1097/COC.0b013e3182610878&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B71-biomedicines-10-01321">
<span class="label">71.</span><cite>Hanna G., Murray L., Patel R., Jain S., Aitken K., Franks K., van As N., Tree A., Hatfield P., Harrow S., et al.  UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy. Clin. Oncol. 2018;30:5–14. doi: 10.1016/j.clon.2017.09.007.</cite> [<a href="https://doi.org/10.1016/j.clon.2017.09.007" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29033164/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin.%20Oncol.&amp;title=UK%20Consensus%20on%20Normal%20Tissue%20Dose%20Constraints%20for%20Stereotactic%20Radiotherapy&amp;author=G.%20Hanna&amp;author=L.%20Murray&amp;author=R.%20Patel&amp;author=S.%20Jain&amp;author=K.%20Aitken&amp;volume=30&amp;publication_year=2018&amp;pages=5-14&amp;pmid=29033164&amp;doi=10.1016/j.clon.2017.09.007&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B72-biomedicines-10-01321">
<span class="label">72.</span><cite>Common Terminology Criteria for Adverse Events (CTCAE)—Version 4.0 Published: 28 May 2009 (v4.02: 15 September 2009)—U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute.  [(accessed on 28 May 2009)].  Available online:  <a href="https://www.eortc.be/services/doc/ctc/ctcae_4.03_2010-06-14_quickreference_5x7.pdf" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.eortc.be/services/doc/ctc/ctcae_4.03_2010-06-14_quickreference_5x7.pdf</a>.</cite>
</li>
</ul></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adda93_" lang="en" class="data-availability-statement"><h3 class="pmc_sec_title">Data Availability Statement</h3>
<p>The data presented in this study are available on request from the corresponding author. The data are not publicly available due to Institutional policies, and the need for the authorization of the Study Coordinator (L.T. and S.M.M.).</p></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from Biomedicines are provided here courtesy of <strong>Multidisciplinary Digital Publishing Institute  (MDPI)</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.3390/biomedicines10061321"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/biomedicines-10-01321.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (2.0 MB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/9219949/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/9219949/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC9219949%2F%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC9219949/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC9219949/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC9219949/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/35740343/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC9219949/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/35740343/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC9219949/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/9219949/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="UYIcLBlLZGIg7siA6UvImCrUc2dn3Rrxw88pxtOjgocAiyNBmTTiTKkAjUCA6CW2">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Web Policies
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            FOIA
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS Vulnerability Disclosure
        

        
    </a>


                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Help
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Accessibility
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Careers
        

        
    </a>


                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NLM
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NIH
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            USA.gov
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-133c6271.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-44d04358.js"></script>
    
    

    </body>
</html>
